

1 **COVID-19 convalescent plasma and randomized clinical trials: explaining conflicting outcomes**  
2 **and finding signals of efficacy.**

3

4 Daniele Focosi<sup>1,#</sup>

5 Massimo Franchini<sup>2</sup>

6 Liise-anne Pirofski<sup>3</sup>

7 Thierry Burnouf<sup>4</sup>

8 Nigel Paneth<sup>5</sup>

9 Michael J. Joyner<sup>6</sup>

10 Arturo Casadevall<sup>7</sup>

11

12 <sup>1</sup>North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.

13 <sup>2</sup>Division of Transfusion Medicine, Carlo Poma Hospital, 46100 Mantua, Italy;

14 [massimo.franchini@asst-mantova.it](mailto:massimo.franchini@asst-mantova.it)

15 <sup>3</sup>Division of Infectious Diseases, Albert Einstein College of Medicine and Montefiore Medical Center,

16 New York, NY 10467, USA; [l.pirofski@einsteinmed.org](mailto:l.pirofski@einsteinmed.org)

17 <sup>4</sup>Graduate Institute of Biomedical Materials and Tissue Engineering & International PhD Program in

18 Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei,

19 Taiwan; [thburnouf@gmail.com](mailto:thburnouf@gmail.com)

20 <sup>5</sup>Departments of Epidemiology & Biostatistics and Pediatrics & Human Development, College of

21 Human Medicine, Michigan State University, East Lansing, MI 48824, [paneth@msu.edu](mailto:paneth@msu.edu)

22 <sup>6</sup>Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA;

23 [joyner.michael@mayo.edu](mailto:joyner.michael@mayo.edu)

24 <sup>7</sup>Department of Medicine, Johns Hopkins School of Public Health and School of Medicine, Baltimore,

25 MD, USA; [acasade1@jhu.edu](mailto:acasade1@jhu.edu)

26

27 <sup>#</sup>corresponding author: via Paradisa 2, 56124 Pisa, Italy. E-mail: [daniele.focosi@gmail.com](mailto:daniele.focosi@gmail.com)

28

29 **Word count:** abstract 283; body 5835.

30 **Keywords:** COVID-19; convalescent plasma; randomized clinical trial; propensity score-matched;  
31 neutralizing antibodies; viral neutralization tests.

32 **Abbreviations:** BSC : best supportive care; CP : convalescent plasma; CCP : COVID-19  
33 convalescent plasma; nAbs : neutralizing antibodies; VNT: viral neutralization test;

34 **Author contributions:** D.F. designed the paper, analyzed the data, and wrote the first draft. M.F.,  
35 M.J.J., T.B., L.P., N.P. and A.C. revised the manuscript. All authors approved the final version.

36

37

38 **Abstract**

39 Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is available as  
40 soon as there are survivors. The COVID-19 pandemic represented the first large-scale opportunity to  
41 shed light into mechanisms of action, safety and efficacy of CP using modern evidence-based  
42 medicine approaches. Studies ranging from observational case series to randomized controlled trials  
43 (RCT) have reported highly variable efficacy results for COVID-19 CP (CCP), resulting in uncertainty.  
44 Reasons for CCP success and failure may be hidden in study details, which are usually difficult to  
45 explain to physicians and the public but provide fertile ground for designing next-generation studies.  
46 ~~In this paper~~ We analyzed variables associated with efficacy such as clinical settings, disease  
47 severity, CCP SARS-CoV-2 antibody levels and function, dose, timing of administration (variously  
48 defined as time from onset of symptoms, molecular diagnosis, diagnosis of pneumonia, or  
49 hospitalization, or by serostatus), outcomes (defined as hospitalization, requirement for ventilation,  
50 clinical improvement or mortality), CCP provenance and time for collection, and criteria for efficacy.  
51 Focusing only on the results from the 30 available RCTs we noted that these were more likely to show  
52 signals of efficacy, including reductions in mortality, if the plasma neutralizing titer was  $\geq 160$  and the  
53 time to randomization was  $\leq 9$  days, consistent with passive antibody therapy efficacy requiring  
54 dosing with sufficient antibody. The fact that most studies revealed signals of efficacy despite  
55 variability in CCP and its use suggest likely therapeutic effects that become apparent despite the data  
56 noise. Despite the recent WHO guidelines discouraging CCP usage, the Omicron variant of concern  
57 is reminding us the superiority of polyclonal antibody therapies over monoclonal antibodies, and CCP  
58 from vaccinated convalescents is likely to be evaluated soon

59	Table of contents	
60	Introduction.....	4
61	Methods .....	5
62	Results .....	6
63	The indication.....	6
64	The therapeutic dose .....	7
65	Relevance of CCP to the viral variant .....	10
66	The intended outcomes.....	11
67	Analyzing conflicting outcomes in individual RCTs.....	12
68	The inadequacy of meta-analyses.....	14
69	Recommendations .....	17
70	The future of CCP .....	18
71	Figure 1 .....	20
72	Figure 2 .....	22
73	Table 1 .....	24
74	Table 2 .....	29
75	Table 3 .....	39
76	Table 4 .....	42
77	References.....	44

78

## 79 Introduction

80 In the first 21 years of the 21<sup>st</sup> century humanity has experienced six major multinational epidemics.  
81 The agents involved were SARS-CoV, MERS-CoV, influenza A(H<sub>1</sub>N<sub>1</sub>), Ebola, Zika and SARS-CoV-2  
82 viruses. For the five most lethal of these outbreaks the response included the use of convalescent  
83 plasma (CP) (reviewed in (1, 2)) and it was considered for the less lethal sixth (Zika virus). The  
84 attraction of CP is that it is readily available as soon as there are convalescing survivors, that unlike  
85 drugs or monoclonal antibodies it needs no development, and it is polyclonal, affordable and  
86 deployable even in resource poor countries. Despite suffering from some logistical hurdles (dedicated  
87 collection, testing and handling procedures, heterogeneity, standardization of the therapeutic dose,  
88 blood type matching, and intravenous delivery), CP has been proposed as a first line response to new  
89 pandemics (3) and was deployed during the COVID-19 pandemic in March 2020 in countries that  
90 experienced the early waves of disease such as China (4, 5) and Italy (6). The relatively low COVID-  
91 19 case-fatality rate (compared to the other epidemic agents noted above) allowed for testing of CP  
92 across a wider spectrum of disease severity.

93 While in early 2020 most clinical use was reported in case series or small phase II clinical trials (7),  
94 beginning in late March 2020 the US expanded access program (EAP) generated a large and robust  
95 treatment dataset, with insights on safety and optimal use. This database provided the first clear  
96 evidence that CP is safe, which was important given that early in the pandemic there were significant  
97 concerns about antibody-dependent enhancement (8). Later, an analysis of the first 3082 patients  
98 within the EAP database provided evidence that associated early administration of high titer CCP to  
99 non-ventilated hospitalized patients with reduced mortality (9). Before the FDA granted emergency  
100 use authorization (EUA), the US EAP provided CCP to as many as 94,287 patients.

101 During the past year, many studies employing either randomized controls (RCT) or propensity score-  
102 matched (PSM) controls have been published. RCTs and PSM studies reported so far have had  
103 largely opposite outcomes, with most but not all RCTs finding little overall effect on mortality while the  
104 PSM and many smaller trials reporting mortality benefits. Several RCTs did not have mortality as a  
105 primary endpoint or it was part of a composite endpoint (5, 10-12). These disparate results have led to  
106 confusion for both the public and the clinicians, leading to reduced enthusiasm for the use of CP, in  
107 part because RCT data is more influential in affecting the opinion of many physicians, specialty  
108 societies and government regulators.

109 As with any other medical treatment, several key factors should be taken into account when  
110 evaluating a trial, including the indication (which can be estimated by timing or clinical severity), the  
111 therapeutic dose and the intended outcomes. The choices made by the trial designers determine  
112 whether the trial will demonstrate clinical benefit. While much attention is appropriately focused on  
113 the performance features of clinical trials (sample size, fidelity to randomization, appropriate analysis),  
114 the biological rationale for the hypothesis being tested is critically important but not always taken into  
115 account.

116

## 117 **Methods**

118 On December 13, 2021, we searched PubMed (which is also indexing the medRxiv prepublishing  
119 server) for clinical trials of CCP in COVID19, focusing on RCTs and PSM studies only. Each study  
120 was analyzed for the following variables: NCT identifier, recruitment, randomization strategy, type of  
121 control arm, baseline patient status, median neutralizing antibody (nAb) titer in both recipients (before  
122 CCP transfusion) and CCP units, type of viral neutralization test (VNT), primary endpoint, signals of  
123 efficacy, and reasons for failure

124 At the same date, the ClinicalTrials.gov database was searched for CCP RCTs worldwide having as  
125 status “completed”, “active, not yet recruiting” or “recruiting”.

126

## 127 Results

128 PubMed search retrieved 28 RCTs and 13 PSM studies about CCP, whose main variables are  
129 summarized in Tables 2 and 3. The characteristics of the VNTs used are summarized in Table 1. The  
130 variables were reconciled in 4 major topics, discussed in the following sections: the indication, the  
131 therapeutic doses, the relevance of CCP to the viral variant, and the intended outcome.

132 ClinicalTrials.gov search retrieved 7 CCP RCTs completed but not yet prepublished or published, 5  
133 active but not yet recruiting RCTs, and 12 RCTs which are still recruiting (summarized in Table 4).

### 134 The indication

135 While it would be desirable to have a single drug that works at any disease stage, it was not  
136 reasonable to expect neutralizing antibody (nAb)-based treatments such as CCP to have a significant  
137 effect in later stages of disease. COVID-19 is now well-defined as a disease with two stages, an initial  
138 viral phase characterized by flu-like and upper and lower respiratory symptoms, followed, in severe  
139 cases, by an inflammatory phase that is characterized by inflammation-driven damage to multiple  
140 organ systems, including the lungs that can impair gas exchange and cause life-threatening hypoxia  
141 and damage to multiple organs, including the brain and blood vessels (13). Accordingly, lack of  
142 endogenous nAb at baseline has been associated with a higher risk of viremia, but Marconato *et al*  
143 showed that CCP recipients benefit from high-titer CCP even after adjusting for their endogenous nAb  
144 (14). Specific intact antibodies in CCP are expected to neutralize SARS-CoV-2 in the intravascular  
145 system and, in some patients, prevent progression from early to severe and life-threatening disease  
146 (as seen in animal models (15-17)). However, this antiviral therapy cannot be expected to reverse the  
147 inflammatory phase of the disease, nor neutralize infectious viruses invading the extravascular  
148 system. Thus, COVID-19 is similar to influenza, a disease in which antivirals are effective early in  
149 disease but have no effect in later stages when the symptomatology stems largely from the  
150 inflammatory response. The rationale for administering CCP as early as possible in the course of  
151 COVID-19 stems from the neutralization stoichiometry itself: the larger the number of actively  
152 replicating virions in the body, the higher the nAb dose needed for neutralization (18). Some  
153 uncontrolled studies have reported a lack of association between early intervention and outcomes  
154 (19, 20), but in these studies the level of nAb or the overall anti-Spike antibody level in the infused  
155 CCP was unknown, leaving room for alternative explanations.

156 At the beginning of the pandemic, some investigators and opinion leaders, riding the wave of CCP  
157 successes in anecdotal reports in the media and small case series, introduced CCP to the general  
158 public as a panacea for any patient with COVID-19, including life-threatening cases, leading to  
159 confusing messaging: after reports of failure in severely ill patients emerged, opinions became  
160 polarized and the debate became anything but scientific (21). In clinical trials, the indication (i.e., the  
161 baseline clinical setting) has been variously defined by patient status (outpatient vs. presenting to the  
162 emergency room vs. hospitalized vs. ICU-admitted), disease severity (using 5-category COVID-19  
163 Outpatient Ordinal Outcome Scale (22), a 6-category ordinal scale (12), a 7-category COVID-19  
164 severity scale (23), the WHO 8- (24) or 11-category (25) ordinal scales, or pneumological scores such  
165 as SOFA), the time elapsed before recruitment (also variably defined as from molecular diagnosis,

166 from onset of hospitalization, from diagnosis of pneumonia, or from onset of symptoms), or by  
167 serological status (presence of antibodies or the ability to neutralize SARS-CoV-2). This variability in  
168 inclusion criteria for studies has resulted in marked heterogeneity in recruited patients. As shown by  
169 CONTAIN (where those with shorter of symptom durations did worse), symptom duration can a poor  
170 indicator of ‘early’ disease but actually an indication of severe, rapidly progressive disease (26).  
171 Disease severity marked by WHO score as opposed to symptom duration may be a more accurate  
172 tool to capture “early” disease, as supported by the positive results with CCP in low WHO scores  
173 summarized in Figure 1.

174 The vast majority of SARS-CoV-2 infections are mildly symptomatic, so when dealing with outpatients  
175 (WHO categories 1 to 3; the strata which are most likely to benefit from nAb-based therapies), the  
176 number needed to treat (NNTT) in order to prevent a single hospitalization or death can be very large,  
177 and even larger if vaccinees are recruited. In order to be economically and logistically sustainable, it  
178 seems wise to focus on those outpatients having risk factors for disease progression, as done with  
179 COVID19 mAbs. This approach was pursued by C3PO (27) and NCT04479163, but not other  
180 outpatient RCTs (COV-Early (28), CSSC-004 (29)). A special category is represented by outpatients  
181 recruited at the time of ER attendance (e.g. in C3PO (27): they should be considered at the border  
182 between outpatients and inpatients, and hence not aggregated in outpatient metaanalyses. Among  
183 outpatients not recruited at the ER, clinical benefit has been shown up to 6 days since onset of  
184 symptoms (e.g. in the CSSC-004 RCT (29)). No benefit of CCP over FFP has been proven in the  
185 single RCT of post-exposure prophylaxis (CSSC-001) at preventing infection, symptomatic disease,  
186 but the study was not powered to detect a reduction in hospitalization (30).

187 For what concerns inpatients (WHO categories 4 to 9), clinical benefit from antivirals can only be  
188 expected for categories 4 and 5, since from category 6 on the patients require high-flow oxygen and  
189 hence have significant respiratory failure.

190

### 191 **The therapeutic dose**

192 Determining the effective dose of CCP is difficult in a pandemic because the antibody assays and  
193 other tests needed to assess the potency of any antibody product take time to be developed. In  
194 practice, the effective dose is the product of multiple factors, none of which is fully standardized.

195 The first factor is the concentration of the nAbs as measured by a viral neutralization test (VNT). At  
196 the beginning of the pandemic, only a few biosafety level 3 (BSL3) (or higher)-equipped virology  
197 laboratories could run VNT using authentic live SARS-CoV-2 virus: the procedure was time-  
198 consuming (3-5 days) and the reports were operator-dependent. Nowadays, the availability of Spike-  
199 pseudotyped viruses which can be managed under the more widely available BSL-2 laboratories, or  
200 cell-free ACE-2 competition assays, combined with automated (e.g., luminescence-based) readings,  
201 have standardized outcomes and shortened turnaround times (31): however, harmonization between  
202 different assays is still a work in progress (32). The VNT differs according to the type of replication-  
203 competent cell line, the viral isolate used for the challenge (which is critically important when the virus

204 is mutating rapidly as has been the case with emergence of variants of concern), the multiplicity of  
205 infection (i.e., the ratio between the viral inoculum - referred with different measuring units – and the  
206 number of replication-competent cells within each well), the detection system (optic microscopy for  
207 cytopathic effect, immunostaining, quantitative PCR, or luminometer for engineered pseudoviruses),  
208 and finally the threshold of neutralization (50% or 90%). The DAWN-plasma (33), C3PO (27), and  
209 REMAP-CAP (34) RCTs provide clear examples of such heterogeneity, with up to 4 different VNTs  
210 used at different participating laboratories/countries within the same study (see Table 1). It was not  
211 until August 2020, when many trials were already underway, that the FDA Emergency Use  
212 Authorization 26382 defined high-titer CCP on the basis of correlation with a reference standard, the  
213 Broad Institute live-virus, 5-dilution VNT as a 50% inhibitory dilution ( $ID_{50}$ ) of 1:250 or more  
214 (<https://www.fda.gov/media/141481/download> ), and exclusive use of high-titer CCP was formally  
215 recommended by the FDA only on March 9, 2021. Table 1 summarizes the key variables in VNT  
216 employed to date in CCP RCTs. Published trials have varied greatly in their approaches to antibody  
217 quantification whether in measured transfused CCP units or in recipients. Several RCTs performed  
218 nAb titration, but with highly heterogenous methods which makes comparability of doses across  
219 studies difficult. Table 1 attempts to reconcile doses across those trials, showing that they actually  
220 differed more than is apparent by inspection of raw titers.

221 Despite these uncertainties, we can make estimates of likely effective doses based on the available  
222 clinical experience thus far. The lack of utility from low-titer (1:40) CCP in moderate COVID-19 was  
223 confirmed by the PLACID trial (10). As long as a clear therapeutic dose is not identified, it seems  
224 prudent to transfuse units containing nAb titers at least 10-fold higher than the nAb titer measured  
225 before transfusion in recipient serum. Similarly, the ConCOVID RCT showed that CCP units having  
226 nAb titers similar to those of the recipients (1:160) did not confer a clinical benefit (35). CCP units with  
227 an adequate nAb titer (nowadays estimated at  $\geq 1:160$ ) are more easily found among older males who  
228 recovered from a previous symptomatic COVID-19 requiring hospitalization (36, 37): unfortunately,  
229 such donors were poorly represented in the first donation waves, which tended to obtain CCP from  
230 younger donors with mild disease, and, presumably lower nAb titers (10).

231 Many trials have relied on high-throughput semi-quantitative or qualitative assays with a poor-to-  
232 moderate relationship with nAb titers. Harmonization of such high-throughput assays using the WHO  
233 International Standard of binding arbitrary units (BAU) is nowadays possible (38). Although most trials  
234 performed a correlation analysis between VNT and high-throughput serological assays, in many  
235 cases the CCP units were tested only with the latter without validation, as was the case with 66% of  
236 the patients in the PlasmAR trial (12). This procedure risks an incorrect evaluation of the neutralizing  
237 CCP activity. Another cause for discrepancies in outcomes could be that although IgM, IgG, and IgA  
238 are all capable of mediating neutralization, VNT titers correlate better with binding levels of IgM and  
239 IgA<sub>1</sub> than they do with IgG (39). By contrast, routinely used high-throughput serological assays only  
240 quantify IgG, including non-neutralizing IgGs, whose potency against SARS-CoV-2 has not been  
241 established. Trials should preferentially use VNTs to assess serostatus of transfused units and not  
242 rely on high-throughput serology. As for any other medicinal product, CCP exhibits a dose-response



243 relationship, which is also evident when using high-throughput assays. In the subgroup analysis of the  
244 EAP, a gradient of mortality was seen in relation to IgG antibody levels in the transfused CCP. In the  
245 subgroup of patients who were not receiving mechanical ventilation, death within 30 days after CCP  
246 transfusion occurred in 81 of 365 patients (22.2%; 95% CI, 18.2 to 26.7) in the low titer group, 251 of  
247 1297 patients (19.4%; 95% CI, 17.3 to 21.6) in the medium-titer group, and 50 of 352 patients (14.2%;  
248 95% CI, 10.9 to 18.2) in the high-titer group. Depending on the statistical model, the RR for 30-day  
249 mortality in high-titer CCP compared to low-titer CCP recipients ranged from 0.64 – 0.67, with an  
250 upper 95% confidence bound of 0.91 (8). Similarly, the large retrospective PSM study from Hospital  
251 Corporation of America (HCA) Healthcare-affiliated hospitals reported a 0.2% decreased risk of  
252 mortality for every 1 unit of S/Co serology level (40).

253 An additional limit is testing nAbs only at the time of first donation (e.g., in ConCOVID (35)) while  
254 leaving donors opportunities to repeat donation for months: given the expected decline of nAb levels  
255 in time in convalescents, this could have overestimated the actual dose.

256 The nAb titer (or total IgG levels as measured by surrogate assays) only describes one factor involved  
257 in defining the real therapeutic dose in that it represents the concentration of just one (likely the main)  
258 active ingredient. But CCP contains additional antibodies that mediate antibody-dependent cellular  
259 cytotoxicity (ADCC), complement activation and phagocytosis of viral particles, functions that can  
260 each contribute to its antiviral effects (41). At this time the relative importance of nAbs vs. the other  
261 antibody activities is not understood, but, hopefully, retrospective analyses that correlate CCP efficacy  
262 with these activities will reveal additional variables that need to be considered in choosing optimal  
263 CCP units. This has relevance when assessing interfering factors: e.g., the impact of pathogen  
264 reduction technologies (PRT) on nAb has experimentally been shown to be apparently minimal (42,  
265 43), but their impact on Fc-dependent functions (such as ADCC) is still to be investigated and could  
266 be relevant for some PRTs (44) (used e.g. in TSUNAMI (45), NCT04356534 (46), and ConPlas-19  
267 (47)). In this regard, we note that an early study reported that methylene blue reduced the protective  
268 function of antibodies to pneumococcus by interfering with glycosylated domains, raising concerns  
269 that it could affect Fc function (44). Of relevance, the various pathogen-reduced plasma went through  
270 clinical evaluation to assess their hemostatic activity linked to coagulation factors, or, at best, Fc  
271 binding to receptors (48), not their immunological activity : furthermore, none of the photochemical  
272 processes used for CCP is used in the field of plasma fractionation, and therefore we cannot make  
273 inferences from pharmaceutical-grade immunoglobulins.

274 The therapeutic dose of nAb is a product of its concentration in the infused CP multiplied by the  
275 overall infused CP volume, adjusted to the recipient body weight to take account of dilution into the  
276 blood volume and tissues. RCTs have varied in the provision of volume per unit (200-300 ml), and  
277 most importantly in cumulative volume per patient (1-4 units) and in extent of exposure to diverse  
278 antibodies from various CCP donors, and no published trials have adjusted levels of nAbs by recipient  
279 body weight (or, when attempts have been performed, they referred to the historical 10-15 ml/kg dose  
280 derived from the treatment of hemorrhagic coagulopathies (49)). A failure of CCP to improve outcomes  
281 when 200-ml of 1:160 nAb-titer CCP is provided to a patient who weighs 120 kg represents quite a

282 different scenario from failure of a 600-ml transfusion of 1:640 nAb-titer CCP to produce improvement  
283 in a 60-kg patient. But these central issues in dosage have not been considered in the RCTs  
284 published so far.

285 Finally, antibodies other than nAbs can play a prominent role in viral clearance. Bahnan *et al* have  
286 shown that CCP and anti-Spike mAbs induce phagocytosis but with diminishing returns when the  
287 antibody concentrations become high: activation and inhibition of phagocytosis are independent of  
288 neutralization potential and humanized ACE2 mice are protected from intranasal challenge by non-  
289 neutralizing antibodies (50).

290

### 291 **Relevance of CCP to the viral variant**

292 Albeit not formally demonstrated, CCP manufactured by pooling ABO-matched units from many  
293 different donors (e.g., in PlasmAr (12)) theoretically have greater polyclonality of nAbs than repeated  
294 CCP doses from a single-donor (e.g. CAPSID (51)) and should grant higher efficacy against viral  
295 variants. Nevertheless, pooling typically occurs among donors attending the same blood bank,  
296 making donor exposure to different viral variants unlikely.

297 An analysis of potential variables associated with CCP efficacy associated near-sourcing with  
298 reduced mortality, with the efficacy of CCP in reducing mortality falling sharply when the CCP source  
299 was more than 150 miles from where it was used (52). This finding suggests that SARS-CoV-2  
300 variants at some geographic locations create antibody responses in CCP that are not effective against  
301 other variants at different locations (53, 54). Even though CCP is often standardized for nAb titer to  
302 the Spike protein, the VNT could use a nonrelevant viral strain, or miss major functional differences  
303 for the antibody response (41). This finding has implication for RCTs that use nationally sourced  
304 (centralized) CCP, since the attempt to standardize the therapeutic units centrally could inadvertently  
305 reduce CCP efficacy if hospitals use CCP obtained from distant loci. For example, in the C3PO RCT,  
306 which was conducted in 21 USA states, 95% of the donor CCP was collected in either Chicago or  
307 Denver: since only 4 of the 48 centers were in Illinois or Colorado, most CCP usage had to be from  
308 remote sources (27). The same concern applies to large multinational RCTs such as REMAP-CAP  
309 (34). By contrast, the NCT04359810 RCT in New York and Brazil, which found a beneficial effect of  
310 CCP on mortality, used CCP locally sourced in New York, whose efficacy against P.1 was tested to  
311 ensure efficacy at the other recruiting center in Brazil (11).

312 Although also not formally demonstrated during clinical trials, it is also reasonable to assume that  
313 CCP collected during early pandemic waves could be less effective against currently circulating  
314 variants of concern (55). RCTs whose recruitment was protracted across multiple pandemic waves  
315 (e.g., ConPlas-19 (47) and TSUNAMI (45)) and which relied on CCP collected and banked months  
316 earlier could have inadvertently used CCP with reduced activity against the SARS-CoV-2 strains  
317 circulating the community when the therapy was administered. No CCP study to date has ever  
318 annotated or retrospectively performed SARS-CoV-2 sequencing on CCP donors nor on patients to  
319 identify the underlying variant: matching of the convalescent donor and the recipient for viral variant

320 has never been formally achieved. Hence, both geography and time of collection of the CCP are  
321 important variables when considering the efficacy of the treatment.

322

### 323 **The intended outcomes**

324 Most trials (CONTAIN (26) and PassItOn being exceptions) have used composite endpoints or  
325 specialty scores (e.g., SOFA) rather than progression in the simple WHO ordinal scale or mortality,  
326 and many were stopped because of apparent futility at a time when they may have been  
327 underpowered to detect significant benefit. As represented in Figure 2, several studies have reported  
328 overall negative results (panel A) despite the presence of positive signals of efficacy just barely  
329 missing statistical significance (panels B and C). The significance level (i.e.,  $p=0.05$ ) is largely a  
330 socially constructed convention for rejecting the null hypotheses, but it has often been misinterpreted  
331 as a measure of reality by many individuals not familiar with the nuances of statistics. For example,  
332 some CCP studies have concluded that a difference that did not achieve a  $p$  value  $< 0.05$  was an  
333 absence of difference, even when mortality in the CCP arm was ~20-40% lower than in controls (11,  
334 47, 51, 56). This reasoning has played a central role in the polarized views of CCP efficacy and has  
335 impeded subsequent studies from drilling down on positive effects that were observed. The dogged  
336 pursuit of statistical significance, viewed as a measure of reality instead of the actual reality  
337 demonstrated by the data, during a public health emergency dealt a serious blow to studies of CCP  
338 and created significant confusion for clinicians. It is also important to understand that RCTs are  
339 powered to be less tolerant of Type I error than Type II error, which are conventionally set at .05 and  
340 .20, meaning that a Type II error is expected four times as often as a Type I error. This statistical  
341 convention can contribute to the absence of significance in studies that were set up early in the  
342 pandemic when there was little information on expected effects for the various patient populations  
343 studied, when power estimates were only guesses, and the enrolled patients were so heterogeneous  
344 that only subgroups were likely to have responded to CCP treatment. Many studies were originally  
345 designed to enroll inpatients at any disease stage, and it should be no surprise that subgroup  
346 analyses on the groups that were later demonstrated to be more likely to benefit from CCP (e.g., early  
347 treated, seronegative patients, those receiving high nAb titre) were underpowered to reach statistical  
348 significance, as shown by orange color predominance in panel C of Figure 2. Nevertheless, favorable  
349 trends are a shared feature across such trials (5, 11, 12, 27, 47, 49, 51, 56, 57).

350 Rigid adherence to primary outcomes that were often fixed in the early days of the pandemic when  
351 information about disease stage and quality of CCP associated with efficacy were not understood has  
352 contributed further to the confusion. When these outcomes were not met, trials were considered  
353 failures even though there were often signals of efficacy in the data that were not considered as  
354 valuable since these had not been pre-specified, even when they made biological sense. For  
355 example, in the New York-Brazil RCT cited above, CCP did not lower the primary end-point of clinical  
356 status on an ordinal scale, but the statistically significant halving of mortality was acknowledged in the  
357 abstract. Would it have made sense to ignore the strong effect of CCP on mortality in this trial just  
358 because mortality was not selected as a primary outcome? RCTs of mAbs (58) and dexamethasone

359 (59) were designed to achieve a tiny 6% and 4% reduction in mortality, respectively, while several  
360 CCP RCTs failed because their initial assumption in the magnitude of reduced mortality was more  
361 optimistic (e.g. TSUNAMI (45)).

362 Another misunderstood endpoint is viral clearance, defined as the conversion of nasopharyngeal  
363 swabs (NPS) from positive to negative for PCR evidence of SARS-CoV-2 in CCP-treated patients.  
364 While there was early and robust evidence for this effect from CCP (4, 10), sampling NPS too late  
365 after CCP treatment, when the endogenous immune response had also mounted in the control arm,  
366 could miss differences.

367

## 368 Analyzing conflicting outcomes in individual RCTs.

369 We use the word ‘failures’ with care and considerable nuance, since negative trials can be very  
370 important in teaching us about populations that do not benefit from CCP or variables that affect its  
371 efficacy. Keeping the factors discussed above in mind, we have analyzed individual RCTs in detail.  
372 At the very beginning, many historically or internally controlled observational studies showed clinical  
373 benefit from CCP (4-6) and this led the FDA to issue an EAP in March 2020 that was converted into  
374 an emergency use authorization (EUA) in August 23, 2020. The largest observational study is the US  
375 open-label EAP (NCT04338360) led by Joyner *et al*, which enrolled 105,717 hospitalized patients with  
376 severe or life-threatening COVID-19 from April 3 to August 23, 2020 (60). In an analysis of the effect  
377 of antibody in CCP performed independently of the results cited above (8) and using a nAb titer in an  
378 overlapping but non-identical group of EAP patients, the FDA showed that the 7-day mortality in non-  
379 intubated patients who were younger than 80 years of age and were treated within 72 hours after  
380 diagnosis was 6.3% in those receiving high-titer CCP and 11.3% in those receiving low-titer CCP  
381 (<https://www.fda.gov/media/142386/download>).

382 In a later analysis of a larger (N = 35,322) subset of EAP patients, (including 52.3% in the intensive  
383 care unit (ICU) and 27.5% receiving mechanical ventilation), the 7-day mortality rate was 8.7% in  
384 patients transfused within 3 days of diagnosis but 11.9% in patients transfused  $\geq 4$  days after  
385 diagnosis; similar findings were observed in 30-day mortality (21.6% vs. 26.7%) (61). In an EAP study  
386 from Argentina, mortality after CCP was 18.1% among 3,113 patients treated within 3 days since  
387 hospitalization, 30.4% among 1380 patients transfused between days 3-7, and 38.9% among 226  
388 patients transfused after day 7 (62). The major criticism of these results is that controls were neither  
389 randomized nor PSM: hence a difference in the treatment outcome between treated and untreated  
390 groups may be caused by a factor that predicts treatment rather than by the treatment itself. However,  
391 importantly, nAb titer analysis was retrospectively done, both patients and physicians were unaware  
392 of the nAb content in the CCP units used, the results are what would have been expected from the  
393 experience with antibody therapy, and multivariate models were used to adjust for potential  
394 confounders (1). Additionally, given the outline of an optimal use case with this data and the earlier  
395 underpowered RCT by Li *et al* (5), it is unfortunate that due to (a) lack of awareness and (b) logistical  
396 burden associated with protocol adjustments, involving repowering and new patients’ recruitment

397 criteria, later treatment RCTs either continued or initiated without modifications to include newly  
398 available evidence.

399 The highest level of scientific evidence in primary clinical research stems from prospective PSM and  
400 RCTs. PSM studies (Table 3) balance treatment and control groups on a large number of covariates  
401 without losing a large number of observations. Unfortunately, no PSM study to date has investigated  
402 nAb titers by VNT or outpatients. Nevertheless, in 2 retrospective PSM studies from 2 different  
403 hospitals in New York, trends for improved outcomes in non-intubated and those treated within 7 days  
404 since hospitalization (HR 0.33) were observed (63, 64). These findings were later confirmed in a  
405 prospective PSM study from Houston (65, 66). Of interest, a retrospective PSM study from  
406 Providence did not show any benefit, but patients were treated at a median of 7 days after onset of  
407 symptoms (67). Another PSM study from Yale associated CCP with a 35% reduction in mortality (68).  
408 That study is notable in that it included patients on mechanical ventilation who would not normally be  
409 expected to benefit from CCP and the percentage of individuals receiving corticosteroids was very low  
410 since the study was conducted in the early days of the pandemic in the USA. Another PSM from the  
411 Washington DC area found a reduction in mortality with CCP use at both days 14 and 28, which  
412 reached statistical significance at the earlier date (69). Finally, a very large study from 176 community  
413 hospitals affiliated with HCA Healthcare confirmed substantial mortality reduction in hospitalized  
414 patients receiving CCP within 3 days from admission (70).

415 Since PSM only accounts for observed (and observable) covariates, and not latent characteristics,  
416 RCT remains the gold standard for highest-level evidence (Table 2). In the PlasmAr RCT, the small  
417 number of early arrivals (less than 72 hours) showed superior primary and secondary outcomes in the  
418 CCP arm (n= 28) compared to the placebo arm (n=11), but the minimal contribution of this group to  
419 the overall cohort (228 CCP and 105 placebo) made the advantage disappear in the final outcomes at  
420 day 30 (12). In another Argentinean RCT on 160 outpatients older than 65 years of age with mild  
421 COVID-19 who were treated with CCP within 72 hours, progression to severe COVID-19 halved at  
422 day 30 (71). Similar findings were reported in outpatients without risk factors in CSSC-004 (29). An  
423 RCT from India reported that patients younger than 67 treated at a median of 4 days after hospital  
424 admission manifested superior mitigation of hypoxia and survival in the CCP arm (72). Another RCT  
425 in Spain enrolling patients at less than 7 days of hospitalization showed four deaths in the control arm,  
426 none in the CCP arm (47). Similarly, the ConCOVID RCT showed reduced mortality in the CCP arm  
427 (35).

428 An additional complexity in recruitment to CCP trials is time to treatment. Clinical trials involve  
429 administrative requirements and consent procedures, and recruitment to a RCT further requires  
430 randomization, which may produce delays in treatment. CCP therapy requires cross-matching of  
431 blood types, ordering the CCP, which may or may not be available on site, and setting up the  
432 transfusion. This inherent delay from randomization to infusion means that RCTs may build in a  
433 disadvantage for the CCP study arm in the few RCTs using control treatments (e.g. saline or fresh  
434 frozen plasma (FFP)), where controls may have received treatment earlier in the disease course : for  
435 example, FFP was used in NCT04346446 (57), NCT04359810 (11), NCT04344535 (56), COV-Early

436 (28), and CSSC-004 (29) RCTs. ABO-compatible CCP units may be not readily available at the local  
437 blood bank and recruited patients may have to wait for a compatible unit of CCP. These almost  
438 inevitable delays from randomization mean that CCP may be provided later in the illness than is ideal,  
439 and even if the trial intends to treat early, in practice it may not be possible unless the RCT is  
440 designed to deliver plasma immediately after randomization.

441 During a pandemic, moreover, delays in treatment are magnified. The accrual of severely ill patients  
442 in emergency departments and the overwhelmed or even collapsed health care systems can create  
443 long delays from arrival in the emergency room to treatment. In the absence of quick (antigenic or  
444 molecular) tests for SARS-CoV-2, the turnaround time for final confirmation of diagnosis with PCR,  
445 which must often be run in batches, can take several hours. All these factors are likely to impact the  
446 efficacy of CCP treatment. To shorten such time, fully screened CCP collected from eligible donors  
447 (73) could be safely administered within emergency departments shortly after admission and even  
448 before the patient reaches the ward.

449 Figure 2 graphically places the outcomes of RCTs and PSM studies on a Cartesian plot having  
450 timeliness and nAbs dose as variables (if values are disclosed in the reports): this makes immediately  
451 clear that the few successes at reaching the primary endpoints have gathered into the lower right  
452 corner (high nAb dose and early intervention), while the many conflicting outcomes have been  
453 scattered all around (panel A), reflecting lower antibody levels infused or late treatment, or both, with  
454 the latter being the commoner problem. Nevertheless, when we focus on mortality irrespective of  
455 statistical significance (panel B) or focusing on statistical significance (panel C), many more RCTs  
456 showed clear benefits.

457 We will focus here on “failures” as identified by title, abstract and/or press recognition. Narratively, we  
458 could group so-called “failures”, with failure implying inability to demonstrate a favorable outcome to  
459 CCP use, into 4 categories, according to the main reasons:

- 460 1. Trials that transfused insufficient therapeutic doses of CCP due to either low total IgG levels  
461 or low nAb levels (e.g., PLACID (10))
- 462 2. Trials that transfused appropriate doses of CCP but too late, but which nevertheless reported  
463 signals of efficacy (e.g., RECOVERY (49), CAPSID (51), NCT04359810 (11) and TSUNAMI  
464 (45))
- 465 3. Trials that were stopped too early to observe benefit or with inherent design flaws, and/or  
466 were underpowered such that likelihood of success was reduced (e.g., C3PO (27))
- 467 4. Trials in which CCP was used to treat a condition not amenable to antibody intervention, such  
468 as hypoxia that is caused by pulmonary inflammation (e.g., COP20 (74) or REMAP-CAP (34))

469

## 470 The inadequacy of meta-analyses.

471 With all the heterogeneity in key drivers discussed in the former paragraphs, it becomes clear that  
472 secondary research (ranging from umbrella reviews to meta-analyses to systematic reviews), whereby



473 each study is considered at the same level, invariably ends up with biased and divergent conclusions.  
474 This adds confusion to the already complex field of individual trial outcomes. Amazingly, as of  
475 December 21, 2021, PubMed has indexed 26 meta-analyses on CCP efficacy, more than the RCTs  
476 reported at the same date. Until the beginning of 2021, meta-analyses (variably including  
477 observational studies) were generally in favor of CCP (75), but began to be biased towards failure  
478 after publication of the large RECOVERY trial (49), which, by enrolling as many as 11,448 patients,  
479 diluted all the signals from positive RCTs. Clear examples of this phenomenon come from a widely  
480 cited metanalysis from Janiaud *et al* in *JAMA* (76) which included press release data from  
481 RECOVERY, and from the living systematic review by the Cochrane Group (77). The *JAMA* paper  
482 was surely unprecedented in the tradition of meta-analysis, not only because it included a study  
483 based only on a news release (which proved to differ in some important respects from the published  
484 paper), but because it allowed these data from a news release to dominate the entire analysis. At  
485 November 2021, in a follow-up metanalysis from the same group on 16,477 patients from 33 trials,  
486 RECOVERY still weighted 69.8% (78). Several groups attempted to dissect the RECOVERY trial and  
487 others by running subgroup analyses in their systematic reviews (79-81), but these reviews were  
488 unable to restore confidence in CCP efficacy in the clinical community that had been lost because of  
489 the publication of the overall negative findings of RECOVERY and PlasmAr (82). Merely following  
490 such metanalyses, on December 7, 2021 the WHO revised its living guidelines on drugs for  
491 COVID19, discouraging usage of CCP (83): such contraindication received large criticisms from both  
492 the SUPPORT-E (84) and CCPP19 consortia.

493 Actually, metanalyses embedding more recent studies and performing subgroup analysis were more  
494 positive on the beneficial effects of CCP. A metanalysis of 22,591 patients (enrolled in 10 RCTs and  
495 15 observational studies) showed that early CCP significantly reduced mortality (RR 0.72,  
496  $p < 0.00001$ ), but only in patients who were not suffering severe or critical disease (85). Another  
497 metanalysis of 18 peer-review clinical trials, 3 preprints, and 26 observational studies actually found  
498 that CCP use was associated with reduced risk of all-cause mortality in severe or critical COVID-19  
499 patients (86). A recent umbrella review of 29 metanalyses and systematic reviews found evidences  
500 for improvement in the CCP arms for some outcomes (overall mortality, viral clearance at day 3,) but  
501 not for others (clinical improvement, length of hospital stay (87).

502 Rather than pooling published RCTs, the Continuous Monitoring of Pooled International Trials of  
503 Convalescent Plasma for COVID-19 Hospitalized Patients (COMPILE) study pooled individual patient  
504 data from ongoing RCTs at two-week intervals. Unfortunately, with the single exception of CONTAIN  
505 (26), participating RCTs largely shared usage in advanced disease stages (DAWN-plasma (33),  
506 PLACID (10), ConCOVID (35), ConPlas-19 (47), NCT04421404, PennCCP2 (88), and the Brasília  
507 Covid-19 Convalescent Plasma (BCCP)) (89).

508 Current clinical utility of CCP While CCP contains a plethora of biologically active molecules (90), we  
509 now have very strong evidence that appropriately vetted CCP from eligible convalescent donors is  
510 safe for patients (91, 92), with no evidence of increased risks of transfusion-transmitted acute lung  
511 injury, antibody-mediated enhancement concerns feared in the early days of the pandemic (93) nor is

512 there evidence that CCP induces accelerated SARS-CoV-2 evolution (11). Polyclonal antibodies such  
513 as CCP are likely to offer better protection against onset of variants than monoclonal antibodies (94-  
514 96): importantly, Pommeret *et al* showed that CCP can rescue immune escape variants emerged  
515 during treatments with bamlanivimab/etesevimab cocktail (97). Outcomes in immunocompromised  
516 patients treated with CCP have been successful in the long-term, with minimal evidence for immune  
517 escape (98).

518 We have also learned that CCP is less likely to benefit patients requiring oxygen (i.e., from level 4 and  
519 up on the 11-point WHO ordinal scale), and hence, ideally, the focus should be on outpatients and in  
520 identifying that subset of patients who seek hospital care and are still sufficiently early in the course of  
521 disease such that they can benefit from CCP. This finding parallels the finding with hyperimmune  
522 serum and anti-Spike monoclonal antibodies, which at first failed in hospitalized patients (99, 100), but  
523 later succeeded for ambulatory patients with mild to moderate COVID-19 (101) and were approved for  
524 emergency use. However, at this moment clinical use in the US is restricted by the FDA to inpatients.

525 CCP usage per admission peaked after issuance of the EUA, with more than 40% of inpatients  
526 estimated to have received CCP between late September and early November 2020. Oladunjoye *et al*  
527 showed that mortality in the second wave in USA, when utilization of corticosteroids, remdesivir and  
528 convalescent plasma was higher, was lower than the first wave (102). However, following reports of  
529 RCTs that failed to show clear benefit from CCP, usage per admissions declined steadily to a nadir of  
530 less than 10% in March 2021. A strong inverse correlation (Pearson correlation coefficient of -0.5176  
531 with  $P = 0.00242$ ) was found between CCP usage and deaths occurring 2 weeks after admission,  
532 and this finding was robust to examination of deaths taking place 1, 2 or 3 weeks after admission.  
533 Changes in the number of hospital admissions, prevalence of variants, and age of patients could not  
534 explain these findings. The authors estimated that the retreat from CCP usage, a phenomenon they  
535 termed “plasma hesitancy”, might have resulted in 29,000 to 36,000 excess deaths in the period from  
536 mid-November 2020 to February 2021 (103). The same analysis estimated that USA had avoided  
537 96,000 excess deaths from August 2020 to March 2021 by its liberal deployment of CCP.

538 Several lines of evidence, ranging from the EAP to clinical trials employing RCT or PSM controls are  
539 now indicating how CCP should be used in immunocompetent patients (104). The evidence supports  
540 the initiation of CCP treatment as early as 44-72 hours within onset of symptoms (which largely  
541 pertains to outpatients) and using CCP with a nAb titer > 1:160. Benefit within 1 week from onset of  
542 symptoms (including in hospitalized patients) is less well understood, although a benefit from higher  
543 therapeutic doses cannot be ruled out at this stage. Clinical benefit seems absent when administered  
544 after 1 week from onset of symptoms or in patients requiring ventilation, or in those who receive CCP  
545 with a low nAb titer. Nevertheless, chronically immunosuppressed patients benefit from CCP even at  
546 later stages (98, 105, 106) : the best evidence for this scenario comes from a prospective PSM  
547 showing a halving of mortality in ICU-admitted oncohematological COVID-19 patients who received  
548 CCP (107). We note that while there have been concerns that use in immunocompromised can  
549 promote the emergence of antibody-resistant variants, such variants have emerged from massive  
550 replication in susceptible populations and not from treated patients, who in any case are isolated in



551 hospitals where mitigation efforts to reduce transmission are employed, and are thus very unlikely to  
552 transmit their viruses further (108). Such simple concepts have been poorly communicated to the  
553 general public and the clinical community, who should be better informed on the settings where CCP  
554 has shown efficacy and the ones where it has not.

555

## 556 Recommendations

557 Stopping trials for futility is an occurrence that deserves special attention, because it represents  
558 wasted resources during a pandemic. Eight RCTs so far have been halted for futility, namely  
559 RECOVERY (49), REMAP-CAP (34), CONCOR-1 (109), C3PO (27), NCT04361253 (ESCAPE), CoV-  
560 Early (28), and COP20 (74), with the first one being to date the strongest evidence for futility (49), with  
561 its massive recruitment affecting the outcomes of systematic reviews (76). Instead of stopping trials  
562 for futility based on pre-set endpoints it makes more sense that DSMBs facing a high likelihood of lack  
563 of statistical significance provide advice on trial modifications that are likely to amplify the significance  
564 of signals of efficacy evident in these studies. This would seem a more responsible action than trial  
565 cessation given the paucity of therapeutic alternatives in the pandemic emergency.

566 More flexibility is needed when dealing with a new virus since estimates of efficacy and the required  
567 power can change tremendously as the data accumulates. For example, some RCTs were designed  
568 to evaluate efficacy at day 15 but subsequently we learned that this time was too early since mortality  
569 often occurs later (26). Indeed, a Bayesian re-analysis of RECOVERY data with a wide variety of  
570 priors (vague, optimistic, skeptical and pessimistic) calculated the posterior probability for both any  
571 benefit or a modest benefit (number needed to treat of 100). Across all patients, when analyzed with a  
572 vague prior, the likelihood of any benefit or a modest benefit was estimated to be 64% and 18%  
573 respectively. In contrast, in the seronegative subgroup, the likelihood of any benefit or a modest  
574 benefit was estimated to be 90% and 74% (79). This finding of benefit accruing to specific sub-  
575 groups, who were not determined post-hoc but because they were likely to benefit based on  
576 understanding of principles of CP treatment is found in nearly every trial whose overall finding is  
577 negative. This effect is more reflective of a problem with RCT design and execution than a limitation  
578 on the efficacy of CCP. Although we agree that subgroup analysis carries the risk of 'cherry picking'  
579 data, such analyses are often important for hypothesis generation and critically important during the  
580 emergency of a pandemic where neither viral pathogenesis nor therapeutic variables are well  
581 understood. When sub-group analyses are based on firm biological principles, such as focusing on  
582 those treated early in disease or lacking their own serological response, the exercise may be  
583 warranted. To emphasize this point, Christopher Columbus missed the pre-specified primary endpoint  
584 of his mission - reaching India - but no one considers his discovery of the New World to be a failure!  
585 Turning to the clinical arena, most trials of anticoagulants in myocardial infarction found reductions in  
586 mortality of about 20-25%, which was generally not significant in these underpowered trials that  
587 declared the findings to be null, even though such a mortality reduction would clearly be of value  
588 (110). Given that conventional peer-review slows down during a pandemic, pre-publishing RCT  
589 results by the preprint mechanism should be encouraged to accelerate sharing of potentially life-

590 saving therapeutic approaches and to provide pre-publication review that could improve the quality of  
591 the final published study.

## 592 The future of CCP

593 CCP remains a relatively inexpensive therapy that is available throughout the world even in resource  
594 poor areas that cannot afford expensive antiviral drugs or monoclonal antibody therapies. Much has  
595 been learned about the variables that affect CCP efficacy even though, as recounted here, the clinical  
596 efficacy data is mixed. Table 4 lists the RCTs whose outcomes have still to be reported after  
597 completion or which are still recruiting patients. Unfortunately, little new can be expected given that  
598 most of these RCTs were designed to enroll patients having symptoms for more than 7 days. Given  
599 the heterogeneity of the product and the complex variables that contribute to efficacy it is remarkable  
600 that many studies have reported reductions in mortality. This suggests a likely therapeutic effect that  
601 allow signals of efficacy to break through all the noise imposed by variability in the product and its  
602 clinical use. The positive evidence for CCP efficacy cannot be dismissed while in many cases  
603 negative results can be explained. In the absence of good therapeutic options for COVID-19, CCP is  
604 likely to find a niche in the early treatment of disease. Instead of looking for unlikely superiority  
605 outcomes, noninferiority RCTs comparing mAbs versus CCP in early arrivals should be initiated. Such  
606 an RCT is very unlikely to be sponsored by vendor companies, so public institutions should be  
607 sensitized to funding it.

608 There is evidence that vaccinated convalescents may have even higher nAb titers than unvaccinated  
609 convalescents (111), and that nAbs are more effective against VOCs than those from unvaccinated  
610 convalescents (112, 113), offering the promise of expanded success in using CCP. The higher  
611 frequency of high-titer donors would make donor screening more cost-effective. Being collected from  
612 individuals far from hospital discharge, and eventually periodic blood donors, it is unlikely that those  
613 units would benefit from further infectious risk minimization with PRTs, reducing the final cost and  
614 avoiding the previously discussed potential confounder of the inactivation method interfering with  
615 antibody function. Hence future CCP trials that will start after mass vaccination campaigns should  
616 preferentially rely over CCP from vaccinated donors. That said, inclusion of vaccinated individuals  
617 (e.g. CSSC-004 (29)) in future RCTs is also a potentially confounder. Indeed those individuals are at  
618 lower risk, thus increasing the outpatients NNTT to prevent a single disease progression, and also  
619 complicating the identification of seronegative individuals who are more likely to benefit from nAbs.

620 Low-to-middle income countries (LMIC) are likely to benefit the most from CCP, given they cannot  
621 afford massive deployment of mAb or small-chemical antivirals. Research is ongoing to spare some of  
622 cold chain requirements for CCP relying over freeze-dried plasma (FDP), which has been shown to  
623 preserve nAb functions for months at ambient temperature (114).

624 On November 8, 2021, the sudden emergence of the SARS-CoV-2 Omicron VOC with its 32 Spike  
625 mutations was an alarming development because it threatened to prolong the pandemic and  
626 undermine the immunity gains made with vaccination campaigns. Computer modeling and *in vitro*  
627 VNT soon confirmed full escape from clinically used mAb cocktails (including


628 bamlanivimab+etesevimab, REGN-CoV-2 and AZD7442) (115, 116). While it was already known that  
629 mAb cocktails were less likely to experience immune escape than single mAbs, most of the scientific  
630 community underestimated the risk from major shifts in the 3D Spike structure. Combined with the  
631 lengthy manufacturing and approval process for mAb therapies, such sudden shifts largely hinder  
632 primarily mAb-based therapies, since polyclonal approaches such as CCP are less vulnerable to  
633 losing activity. While even CCP is vulnerable to losing some efficacy with VOC that manifest partial  
634 immune escape, the probability and extend of reduction are far lower (117).

635 Given the experience accumulated with COVID-19, it is almost certain that CCP will again be  
636 considered to deal with the surges yet to come in the current epidemic as well as for the next  
637 epidemic. One of the good legacies of the COVID-19 pandemic is that an enormous international  
638 research effort had produced a large body of data that teaches how to best use CCP. The lessons  
639 learned reinforce the experience of the past, namely that best results are obtained with high titer CCP  
640 administered early in the course of disease. We are hopeful that lessons learned in this pandemic are  
641 heeded such that use and trials focus on the very early use with high-titer CCP.

642 We declare we have no conflict of interest to disclose.

643 **Figure 1**

644 Simplified graphical representation of CCP RCTs reported to date, plotted according to earliness of intervention and disease severity (stratified according to  
645 WHO 11-category ordinal scale (25): 0: uninfected; no viral RNA detected; 1 : asymptomatic; viral RNA detected; 2 : symptomatic; independent ; 3 :  
646 symptomatic; assistance needed; 4 : hospitalized, no oxygen therapy; 5 : hospitalized; oxygen by mask or nasal prongs ; 6 : hospitalized; oxygen by NIV or  
647 high flow; 7 : intubation and mechanical ventilation,  $pO_2/FiO_2 \geq 150$  or  $SpO_2/FiO_2 \geq 200$  ; 8 : mechanical ventilation,  $pO_2/FiO_2 < 150$  (  $SpO_2/FiO_2 < 200$ ) or  
648 vasopressors; 9 : mechanical ventilation  $pO_2/FiO_2 < 150$  and vasopressors, dialysis or ECMO). Green text indicates trials which met the primary endpoint  
649 with statistical significance; orange text indicates trials which failed to meet the primary endpoint but showed statistically nonsignificant trends in favor of CCP;  
650 red text indicates trials which failed to show and benefit from CCP in the primary endpoint.






651  
652  
653

## 654 Figure 2

655 Simplified graphical representation of CCP RCTs reported to date, plotted according to earliness of intervention and nAb titers in CCP. In **panel A**, green text  
656 indicates trials which met the primary endpoint with statistical significance; orange text indicates trials which failed to meet the primary endpoint but showed  
657 statistically nonsignificant trends in favor of CCP; red text indicates trials which failed to show and benefit from CCP in the primary endpoint. In **panel B**,  
658 green text indicates trials which showed overall mortality benefit from CCP; orange text indicates trials which showed mortality benefit from CCP in the  
659 subgroup of early arrivals or higher nAb titers; red text indicates trials which failed to show any mortality benefit from CCP. In **panel C**, green text indicates  
660 trials which showed statistically significant mortality benefit from CCP (overall or in the subgroup of early arrivals or higher nAb titers); orange text indicates  
661 trials which showed statistical trends towards mortality benefit from CCP (overall or in the subgroup of early arrivals); red text indicates trials which failed to  
662 show any mortality benefit trend from CCP in any subgroup. Underlined text indicates large trials which were not RCT and for which nAb levels was inferred  
663 from high-throughput serology, but are nevertheless reported as reference studies. Numbers in parenthesis indicate cumulative number of patients enrolled.

664

665



667 **Table 1**  
 668 Details of viral neutralization tests (VNT) employed in CCP RCTs. Information was retrieved from original article (including Supplementary Appendix).  
 669 Whenever not reported, the corresponding author was contacted (marked with \*). If the details could not be retrieved the field is labelled “n.a.” (not available).  
 670 IC: inhibitory concentration. NT: neutralization titer. PFU: plaque-forming unit; PRNT : plaque reduction neutralization test.

	RCT (acronym/first author)	cell line	cells seeded per well	virus lineage	virus per well	multiplicity of infection (MOI)	length of incubation	assay read-out	threshold	protocol reference
authentic live SARS-CoV-2	NeuCoV-NET  NCT04393727 (TSUNAMI)	Vero E6	12,000	SARS-CoV-2/Human/ITA/PAVIA10734/2020 (D614G)	100 TCID <sub>50</sub>	0.01	until the cytopathic effect (CPE) became evident.	CPE	last serum dilution that inhibited SARS-CoV-2 CPE by 90%.	(118)
	NCT04433910 (CAPSID)	Vero E6	n.a.	n.a.	100 PFU	n.a.	3 days	CPE	PRNT <sub>50</sub>	(119)
	Broad Institute on a high throughput platform (BROAD PRNT).  Part of NCT04355767 (C3PO)	Vero E6-TMPRSS2	10,000	SARS-CoV-2 live virus (D614)	n.a.	n.a.	48 hours	N-protein ELISA	samples whose curves lay above 0.5 for all the data points were considered non-neutralizing, with ID <sub>50</sub> =20, while samples whose curves fell below 0.5 were considered highly neutralizing and assigned an ID <sub>50</sub> =10,240.	(120)
	NCT04359810 (O'Donnell)	Vero E6	10,000	2019-nCoV/USA-WA1-2020	100 TCID <sub>50</sub>	0.01	48 hours	Triplex ClI-SARS-CoV-2 rRT-PCR Test, EUA200510).	the highest CCP dilution that prevented virus growth (cycle threshold [Ct] was rated as neutralization titer.	(11)



NCT04348656 (CONCOR-1)	Vero-E6	n.a.	Canada/ON-VIDO-01-2/2020, EPI_ISL_42517	50 PFU	n.a.	72 hours	CPE	PRNT <sub>50</sub>	(109)
NCT04342182 (ConCOVID)	Vero-E6	n.a.	German isolate (GISAID ID EPI_ISL_406862)	400 PFU	n.a.	8 hours	CTL ImmunoSpot Image Analyzer	reciprocal of the highest dilution resulting in a reduction >50% of infected cells (PRNT <sub>50</sub> )	(35)
NCT04429854 (DAWN-plasma)	Vero E6	n.a.	BetaCov/Belgium/Sart-Tilman/2020/1	100 TCID <sub>50</sub>	n.a.	5 days	CPE	PRNT <sub>50</sub>	(121)
		18,000	2019-nCoV-Italy-INMI1	3 TCID <sub>50</sub>	n.a.				(122)
		n.a.	Belgium/GH-B-03021/2020	400 PFU	n.a.	4 days	(123)		
		20,000	Belgium/S1871/2020	100 TCID <sub>50</sub>	n.a.	2 days	anti-N staining	NT <sub>50</sub>	(124, 125)
Australian part of NCT02735707 (REMAP-CAP)	Vero E6	20,000	hCoV/Australia/VIC01/202011 and hCoV/Australia/VIC2089/2020	200 TCID <sub>50</sub>	0.01	3 days	CPE	n.a.	(126)
Canadian part of NCT02735707 (REMAP-CAP)	Vero E6	n.a.	Canada/ON-VIDO-01-2/2020	50 PFU	n.a.	3 days	CPE	n.a.	(127)

	RBR-7f4mt9f	Vero (CCL-81)	50,000	n.a.	n.a.	n.a.	3 days	CPE	n.a.	(128)
Spike pseudotype d viruses	Vitalant Research Institute (VRI) Pseudovirus Neutralization  Part of NCT04355767 (C3PO)	ACE2 and TMPRSS2 expressing HEK293T cells	n.a.	VSV pseudotype d with Wuhan-Hu-1 Spike (D614G mutation and without 21 C-terminal aa)	n.a.	n.a.	18-24 hours	chemiluminescence reader	NT were calculated as a percentage of no-serum control and the NT <sub>50</sub> was estimated from the dilution curve	(120)
	NCT04383535 (PlasmAr)	Vero-CCL81	20,000	VSV pseudotype d with Spike (CoV2pp) and carrying <i>Renilla luciferase</i> gene in place of its G glycoprotein (VSVΔG-rLuc).	n.a.	n.a.	18-22 hours	luminometer	IC <sub>50</sub> is calculated as the midway point between the upper and lower plateaus of the curve. absIC <sub>80</sub> appeared to be a more stringent measure of nAb activity, as some sera that have respectable MN absIC <sub>50</sub> titers never achieve an absIC <sub>80</sub> ; this is due in part to the difference in the dynamic ranges between a luciferase-based assay (≥3 logs RLU/s) and a MN assay (~1.5-log optical density [OD] values corresponding to the amount of viral protein detected).	(129)
	CTRI/2020/04/024775 (PLACID)	Vero CCL-81 293 T/ACE2 cells	10,000	SARS-CoV-2 strain NIV2020770	n.a.	n.a.	36 hours	luminometer	n.a.	(130)
	NCT04345523	Vero E6	5,000	lentivirus	titrate	n.a.	48 hours	luminometer	ID <sub>50</sub> expressed as the highest	(23)

(ConPias-19)			pseudotyped with Spike and luciferase	at 10 ng p24 Gag				eter	dilution of plasma (reciprocal dilution), which resulted in a 50% reduction of luciferase activity compared to control without serum. Sigmoid curves were generated and ID <sub>50</sub> neutralization titers (NT <sub>50</sub> ) were calculated by non-linear regression	
NCT04375098 (Elvira-Balcells)	HEK293T/hACE2	10,000*	HIV-1-Δ19 pseudotyped with Spike (Genebank: QHU36824.1) and luciferase	n.a.	n.a.	48 hours*	luminometer	eter	samples with a neutralizing activity of at least 50% at a 1:160 dilution were considered positive and used to perform titration curves and ID <sub>50</sub> NT calculations	(131)
NCT04344535 (Bennett-Guerrero)	n.a.	n.a.	PRNT and pseudovirus	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	(56)
NCT04600440 (COP20)	Vero E6	10,000	pseudovirus	200 PFU	n.a.	8 hours	Indirect immunofluorescence measured by TROPHOS Plate RUNNER HD®		number of infected cells were quantified and normalized to virus incubated without plasma. IC <sub>50</sub> values were calculated using normalized data and a non-linear fit with variable slope.	(74)
NCT04364737	Vero	n.a.	VSV	n.a.	n.a.	7 hours	automate		IC <sub>50</sub>	(132)

	(CONTAIN)			pseudovirus				d enumerat ion of GFP- positive cells		
--	-----------	--	--	-------------	--	--	--	--	--	--

671  
672  
673  
674  
675

## Table 2

Randomized controlled trials (RCT) of COVID-19 convalescent plasma (CCP) reported to date, listed according to date of (pre-)publication. nAb: neutralizing antibodies. BSC: best supportive care. FFP: fresh frozen (nonconvalescent) plasma. n.a.: not assessed (i.e. antivirus antibodies were assessed only using high-throughput serology). IQR: interquartile range. Moderately late usage is defined as 4-6 days since onset of symptoms, late usage as 7-10 days, very late usage as >10 days.

RCT identifier (acronym/first author)	recruitment (out of expected) (randomization strategy)	control arm (in addition to BSC)	median days before randomization	baseline recipient 8-point WHO score* (24, 25)	transfused CCP volume (ml) (pathogen inactivation)	median nAb titer in CCP units	median pretransfusion nAb titer in recipient	main outcomes reported in abstract or conclusions	likely reason(s) for failure	signals of efficacy	ref
NCT04479163 (Libster)	160 (out of 210) (1:1)	BSC + normal saline	39.6 hours (from symptoms; and > 65 yrs)	2	250	n.a.	n.a.	progression to severe COVID-19 halved at day 30	no failure	main outcome	(71)
BKH-CT-012	49 (1:1)	BSC	< 3 (from RCU admission)	5	400	n.a.	n.a.	duration of infection reduced by 4 days; mortality 1/21 in CCP arm vs 8/28	no failure	main outcome	(133)
CTRI/2020/05/025209 (Raj)	80 (1:1)	BSC	4.2 (from hospital admission)	5	200+200	n.a.	n.a.	immediate mitigation of hypoxia, reduction in hospital stay as well as survival benefit was recorded in severe	no failure	main outcome	(72)

								COVID-19 patients with ARDS aged less than 67 years			
ChiCTR2000029757 (Li)	103 (out of 200) (1:1)	BSC	30 (from symptoms)	5-6	200-	$\geq$ 1:40 (inferred from correlation)	n.a.	no significant difference in 28-day mortality (15.7% vs 24.0%) or time from randomization to day-28 discharge (51.0% vs 36.0%)	moderately late usage	reduced mortality at day 28 only in WHO score 5 patients (HR 2.5); negative conversion rate of viral PCR at 72 hours in 87.2% of the CCP group vs 37.5% of the control group (OR, 11.39)	(5)
NCT04342182 (ConCOVID)	86 (out of 426) (1:1)	BSC	10 from symptoms; 2 from hospitalization	5-6	300	1:320 (PRNT <sub>50</sub> )	1:160 in 79% of recipients (11% seronegative)	no benefit at day 15	very late usage, high rate of seropositives	mortality in CCP group 14% (6 out of 43) vs. 26% in control group (11 out of 43) (OR = 0.47)	(35)
CTRI/2020/04/024775 (PLACID)	464 (1:1)	BSC	6 (from symptoms)	4-5	200+200	1:40	1:90 (17% seronegative)	no benefit at day 28	moderately late usage; high rate of seropositives; extremely low nAb titre in CCP	none	(10)
NCT04345523 (ConPlas-19)	350 (1:1)	BSC	8 (from symptoms)	3 (25%) 4 (75%)	250-300 (methylene blue 46.3%, riboflavin 24%, psoralen 19.6%, unknown	1:292	n.a.	no significant differences in primary endpoint (proportion of patients in categories 5, 6 or 7 (death) at 14 days	underpowered for mortality; primary endpoint set at just 15 days	primary endpoint significant at day +28. Trends for reduced overall mortality (p = 0.087) at day +28, especially in aged > 75 years. Primary and secondary endpoints improved in methylene blue-treated CCP subgroup compared to controls (personal communication)	(47)

					n 10.0%)							
NCT04375 098 (Elvira- Balcells)	58 (1:1)	late CCP	6 (from symptoms)	3-4	200+20 0	≥ 1:160	59% < 1:160 (16% of patients enrolled before day 5 were ≥1:160 vs 60% of those enrolled after day 6	no benefit at day 30 in death, mechanical ventilation or prolonged hospitalization compared to CCP administration only in case of clinical worsening or > 7 days after enrolment	underpowered, moderately late usage	none	(134 )	
NCT04383 535 (PlasmAr)	333 (2:1)	BSC + normal saline	8 (from symptoms)	5	500 (from a pool of up to 5 donors)	1:300 IC <sub>80</sub>	n.a.	no benefit at day 30 (16.2% vs. 31.2%)	moderately late usage	early arrivals (less than 72 hours) showed superior primary and secondary outcomes in the CCP arm (n= 28) compared to the placebo arm (n=11), but the minimal contribution of this group to the overall cohort (228 CCP and 105 placebo) made the advantage disappear in the final outcomes at day 30 (12).	(12)	
NCT04356 534 (AlQahtani )	40 (1:1)	BSC	n.a.	4 (95%) 5 (5%)	200+20 0 methyl ene blue inactiva	n.a.	n.a.	no difference in requirement for ventilation, white blood cell count, LDH, C-reactive protein (CRP),	underpowered; the CP group were a higher risk group with higher ferritin levels	primary outcome measure – ventilation – was required in 6 controls and 4 patients on CCP (risk ratio 0.67 95% CI 0.22 – 2.0, p=0.72); mean time on ventilation was 10.5	(46)	

					ted			troponin, ferritin, D-dimer, procalcitonin, mortality rate at 28 days		days in the control against 8.2 days in patients on CCP (p=0.81).	
NCT04346446 (Bajpai)	29 (1:1)	BSC + FFP	< 3 (from symptoms)	4-5	250+250	n.a.	n.a.	no significant reduction in mortality or hospitalization	nAb measured with surrogate competitive assay (GenScript); beneficial factors in FFP used in control arm (90)	better median improvement in PaO <sub>2</sub> /FI <sub>O</sub> <sub>2</sub> at 48-hours [42 vs 231] and at day 7	(57)
NCT04381936 (RECOVERY)	11558 (1:1)	BSC	9 from symptoms; 2 from hospitalization	4-7	Median 275±75 (81% got 2 units from different donors; 12% 1 unit)	n.a.	35% seronegative	no significant difference in 28-day mortality, progression to invasive mechanical ventilation. Closed for futility	late usage	the risk ratio for patients randomized within 7 days of symptom onset was 0.92 in favor of CCP versus 1.06 in patients randomized later; 0.95 for those randomized within 3 days (personal communication). A reanalysis of seronegative patients (having 10% lower mortality) with a vague prior found that the likelihood of any or modest benefit was 86-68% (79).	(49)
NCT04348656 (CONCOR-1)	940 (out of 1200) (2:1)	BSC	8 from symptoms	4-6	1-2 units each 250-ml	1:250	n.a.	closed for futility (even in the subgroup transfused within 3 days from diagnosis) in intubation or death by day 30	late usage (hypoxemic), sicker CCP arm (more abnormal CXR, more in ICU), varying standard of care across 72 centres in 3 countries	each standard log increase in neutralization or ADCC independently reduced the potential harmful effect of CCP (OR=0.74), while anti-Spike IgG increased it (OR=1.53)	(109)



NCT02735707 (REMAP-CAP)	2011	BSC	≤ 3 from ICU hospitalization	5 (25%) 6 (75%)	2 units (550±150 ml) within 48 hours	≥ 1:80 for Australia; ≥1:160 in Canada; n.a. in UK and USA	In Australia; n.a. in Canada, UK, and USA	no significant difference in median organ support-free days, in-hospital mortality or median number of days alive and free of organ support at day 21. Closed for futility	very late usage	In the small number of participants (n=126) with immunodeficiency at baseline, convalescent plasma demonstrated potential benefit (posterior probability of superiority of 89.8%).	
NCT04355767 (C3PO)	511 (out of 900) with at least 1 risk factor associated with severe COVID-19	BSC	4 from symptoms, presented to the emergency department	2-3	1 250-ml unit	1:641 ID <sub>50</sub>	n.a.	nonsignificant difference in risk difference (1.9%). Outcomes regarding worst illness severity and hospital-free days were similar in the two groups	'all cause' outcome instead of COVID-19-related outcome; centralized CCP supply to distant sites likely affected by different SARS-CoV-2 variants (52) (since only 4 of the 48 centers were in Illinois or Colorado, most CCP usage had to be from remote sources); immunosuppressed individuals were nearly twice as common in the treatment group (12.8% vs 6.7%); designed to detect an absolute risk difference of 10% in disease progression (135)	9.4% reduction in primary event endpoint in CCP group, which rises to 24% after exclusion on patients admitted on the index visit (p = .07). Dyspnea emerged in 6.7% of controls, but in 2.3% of the CCP treated (P < .05). Hospitalizations (including deaths) after the day of treatment were found in 12.8% of the CCP treated but in 19.6% of controls (p = .035). Symptom worsening after the first day occurred in 34.9% of CCP recipients, but in 41.9% of controls (p < .05)	(27, 136)
NCT04359810	223 (2:1)	BSC + FFP	9 from symptoms	5-7	1 200-250 ml	1:160	n.a.	at 28 days, no significant	very late usage; beneficial factors in FFP used in	lower mortality (12.6% vs. 24.6%) compared to	(11)

(O'Donnell )					unit			improvement in clinical status	control arm (90)	nonconvalescent plasma	
NCT04381858 (Gonzalez)	190 (2:1)	BSC + IVIg 1.5 mg/kg	12 from symptoms	6 7 (85%)	2 200-ml units 24 hours apart	n.a. (29.5% received at least 1 unit of CCP with antibodies)	n.a.	no difference in mortality at day 28	very late usage; beneficial factors of IVIg used in control arm	none	(137 )
NCT04344535 (Bennett-Guerrero)	74 (out of 500) (4:1)	BSC + FFP	9 from symptoms, 4 from hospitalization	n.a.	2 200-ml units	1:526	n.a.	no difference in ventilator-free days or mortality (27% vs. 33%) at day 28. Terminated after FDA issued EUA	very late usage; beneficial factors in FFP used in control arm (90)	all-cause mortality through 90 days was numerically lower in the CCP versus standard plasma groups (27% vs 33%; p = 0.63)	(56)
NCT04433910 (CAPSID)	105 (1:1)	BSC	7 from symptoms	4-7	3 units from same donor over 5 days (850 ml)	1:160 (PRNT <sub>50</sub> )	1:160 (PRNT <sub>50</sub> )	not significant difference in the primary outcome (dichotomous composite outcome of survival and no longer fulfilling criteria for severe COVID-19) and secondary outcomes	moderately late usage	median time to clinical improvement was 26 days in the CCP group and 66 days in the control group (p=0.27). Median time to discharge from hospital was 31 days (IQR 16-n.r.) in the CCP and 51 days (IQR 20-n.r.) in the control group (p=0.24). In the subgroup that received a higher cumulative amount of nAbs the primary outcome occurred in 56.0% (versus 32.1%), with a shorter interval to clinical improvement, shorter time	(51)

										to hospital discharge and better survival compared to the control group	
NCT04547660 (PLACOVID)	160 (1:1)	BSC	10 from symptom	37% 5-6 66% 7	2 300-ml aliquots 2 days apart,	n.a.	>1:80 in 83%	no difference in 28-day mortality, days alive, days free of respiratory support, duration of invasive ventilatory support, inflammatory and other laboratorial markers values on days 3, 7 and 14	very late usage	none	(138)
NCT04429854 (DAWN-plasma)	320 (2:1)	BSC	7 from symptoms	3-5	2 200-250 ml aliquots within 12 hours followed by 2 units within 36 hours	n.a.	≥1:320	no significant improvement proportion of patients that require mechanical ventilation or have died at day 15 or 30	late usage	none	(33, 139)
NCT04589949 (CoV-Early; first 20% recruitment aggregate)	421 (out of 690) (1:1)	FFP	≤ 7 from symptoms (median 5?), ≥ 50 years and ≥1 additional factor	2	1 300-ml unit	1:386	93% seronegative (21 vaccinated with 2 doses, 14 with 1	no difference in hospital admission, death or time to resolution (OR = 0.93), regardless of nAb titer	moderately late usage, low titer, low volume; low hospitalization rate (9.3%), hence not powered to exclude a small treatment effect	effect of CP on hospital admission or death was largest in patients with ≤5 days of symptoms (OR 0.658)	(28)

d with the first 20% of ConV-ert RCT)			(outpatients)				dose?)				
NCT04393727 (TSUNAMI)	417 (1:1)	BSC	> 7 from radiological diagnosis	4-5	2 200-ml aliquots (>90% amotosalen; <10% riboflavin-inactivated)	1:226 (each unit > 1:160)	n.a.	no statistically significant improvement in progression to ventilatory support or death	powered to detect an exaggerated 40% reduction in primary endpoint; underpowered for subgroup analysis; late usage; unexplained findings at site 02 (which recruited 40% of patients)	trends favoring CCP in basally seronegatives, P/F > 300 mmHg (p = 0.059), and recipients of units with higher nAb titres	(45)
NCT04600440 (COP20)	31 (out of 100) (1:1)	BSC	< 4 from positive NPS	5	3 200-250 ml aliquots	1:116 (each unit > 1:40)	n.a.	no significant difference in number of days of oxygen treatment to keep SaO2 > 93% or mortality at 28 days. Closed for futility	focusing on patients with worse clinical course (oxygen requiring at day 4 since NPS); largely underpowered; more days passed since onset of symptoms to transfusion	none	(74)
NCT04397757 (PennCCP2)	80 (1:1)	BSC	6 since onset of symptoms, 1 since hospitalization	3-5	2 units on day 1 from 2 different donors	n.a.	n.a. (60% seronegative)	significant benefit by clinical severity score and 28-day mortality (26% vs. 5%) in patient with a median of 3 comorbidities (including	no failure	trends for better WHO8 scores at day 14 and 28, any use of mechanical ventilation or ECMO, duration of mechanical ventilation or ECMO use, and duration of supplemental oxygen use	(88)

								immunodeficiency)			
NCT04373460 (CSSC-004)	1225 (1:1) (out of 1344)	FFP	6 since onset of symptoms (outpatients)	1-3	1 250-ml unit	n.a. (1:14,580 Euroimmun)	n.a.	hospitalization in 6.3% of FFP vs. 2.9% of CCP (RR = 0.46)	no failure	none	(29)
NCT04364737 (CONTAIN)	941 (1:1)	BSC + placebo	7 since onset of symptoms	5	1 250-ml unit	1:93 (70% < 1:160) between April and June 2020)	n.a. (67% seropositive)	no improvement in WHO ordinal scale at day 14 or 28	low-titre (except Q2 and Q5) and low volume; centrally-distributed CCP to states with different viral variants after June 2020; primary endpoint too early at day 14	at day 28, cORs were 0.72 for participants enrolled in Q2 (April-June 2020) and 0.65 for those not receiving remdesivir and not receiving corticosteroids at randomization. At day 28, mortality was lower in 486-seropositive than 242-seronegative participants irrespective of treatment arm, and in seronegative CCP (14.4%) than placebo (17.9%)	(26)
NCT04323800 (CSSC-001)	180 (1:1) (out of 500 because of wide vaccine availability)	BSC + FFP	exposed within 96 h of enrollment and 120 h of receipt of CCP (median 2 days)	0	1 unit	> 1:320	100% seronegative	no reduction in infection or symptomatic disease rate	not powered to show reduction in hospitalization	no COVID-19-related hospitalizations in CCP and 2 in control recipients	

676 \* 0: uninfected; no viral RNA detected; 1 : asymptomatic; viral RNA detected; 2 : symptomatic; independent ; 3 : symptomatic; assistance needed; 4 :  
677 hospitalized, no oxygen therapy; 5 : hospitalized; oxygen by mask or nasal prongs ; 6 : hospitalized; oxygen by NIV or high flow; 7 : intubation and

- 678 mechanical ventilation,  $pO_2/FiO_2 \geq 150$  or  $SpO_2/FiO_2 \geq 200$  ; 8 : mechanical ventilation,  $pO_2/FiO_2 < 150$  (  $SpO_2/FiO_2 < 200$ ) or vasopressors; 9 :
- 679 mechanical ventilation  $pO_2/FiO_2 < 150$  and vasopressors, dialysis or ECMO .

680  
681  
682

### Table 3

Propensity score-matched (PSM) CCP studies reported to date. DPH: days post-hospitalization. None of these studies titrated nAbs in either donor or recipient using VNT. HR : hazard ratio ; OR : odds ratio. aOR : adjusted OR. aHR : adjusted HR.

study design	location	patients+ controls	median days CCP given post-hospitalization	baseline recipient WHO score (24)	transfused CCP volume (ml)	statistically significant outcomes	Reason(s) for failure	ref
retrospective	Mount Sinai, NY, USA	39 + 156	4	5 (87%) 6 (10%)	250+250	on day 14 oxygen requirements worsened in 17.9% of plasma recipients versus 28.2% of controls (aOR 0.86). Survival improved in plasma recipients (aHR 0.34)	No failure	(64)
	Providence, RI, USA	64 + 177	> 2 (< 10 from onset of symptoms: median 7)	4 (70%) 5 (30%)	n.a. (2 units)	no significant differences in incidence of in-hospital mortality (12.5% and 15.8%; aHR 0.93) or overall rate of hospital discharge (RR 1.28, although increased among patients > 65-years)	Late usage	(67)
	Montefiore Medical Center, NY, USA	90 + 258	< 3 (3-7 days from onset of symptoms)	5-6 (< 24 hrs mechanical ventilation)	200	anti-S IgG titer $\geq 1:2,430$ (median 1:47,385) recipients <65 years had 4-fold lower mortality and 4-fold lower deterioration in oxygenation or mortality at day 28	No failure	(63)
	Washington, USA	263+263	< 14	n.a.	245 (median)	reduced 7-day (9.1 vs. 19.8%) and 14-day mortality (14.8 vs. 23.6%), but not 28-day mortality ( $P = 0.06$ ), and longer hospital stay	Late usage; control cohort was treated, on average, 29 days prior to the CCP cohort	(69)
	USA (176 HCA Healthcare-affiliated community hospitals)	3774 + 10687	< 3 vs. 4-7	n.a.	n.a.	lower mortality (aHR = 0.71) and faster recovery. CCP within 3 days after admission, but not 4-7 days, was associated with a significant reduction in mortality risk (aHR = 0.53). CCP serology level was inversely associated with mortality when controlling for interaction with days to transfusion (HR = 0.998) but was not significant in a univariable analysis	No failure	(70)
	China	163 + 163	23	n.a.	300	hospital stay in CCP group was significantly longer than matched control group ( $P < 0.0001$ ).	Very late usage; more advanced disease in the	(140)

							CCP group (23 days vs. 15 since hospital admission)	
	Greece	59 + 59	7	≥ 4	200-233 ml (days 1, 3, and 5)	significantly reduced risk of death [HR: 0.04, 3.4% vs. 13.6%], significantly better overall survival by Kaplan-Meier analysis, and increased probability of extubation [OR: 30.3]. Higher levels of antibodies (as measured with Euroimmun or pseudoVNT) in CCP were independently associated with significantly reduced risk of death.	No failure	(141)
	New Haven, USA	132 + 2551	< 6 vs > 6 days	moderate to severe		early CCP recipients, of whom 31 (40%) were on mechanical ventilation, had lower 14-day (15% vs 23%) and 30-day (38% vs 49%) mortality compared to a matched unexposed cohort, with nearly 50% lower likelihood of in-hospital mortality (HR 0.52). Early plasma recipients had more days alive and ventilator-free at 30 days (+3.3 days) and improved WHO scores at 7 days (-0.8) and hospital discharge (-0.9) compared to the matched unexposed cohort	No failure	(68)
	USA	143+823 (hematologic cancer)	n.a.	n.a.	n.a.	improved 30-day mortality (HR, 0.52; 95% CI, 0.29-0.92). Among the 338 patients admitted to the ICU, mortality was significantly lower in CCP recipients compared with nonrecipients (HR 0.40). Among the 227 patients who required mechanical ventilatory support, mortality was significantly lower in CCP recipients compared with nonrecipients (HR 0.32).	No failure	(107)
prospective	Houston, USA	136 + 251	n.a.	3 (9%) 4 (63%) 5 (18%) 6 (10%)	300 (1-2 units)	reduction in mortality within 28 days, specifically in patients transfused < 72 hours of admission with CCP with an anti-RBD titer ≥1:1350 (i.e., ~80% probability of a live virus <i>in vitro</i> neutralization titer of ≥1:160 (142))	No failure	(65)
		341 + 594	n.a.	7 (1%)	300 (1-2 units)	reduced 28-day (aHR=2.09 for controls) and 60-day (5.7% vs. 10.7%; aHR=1.82 for controls) mortality in	No failure	(66)



						those transfused with anti-RBD $\geq 1:1350$ within 72 hours post-hospitalization. Optimal window of 44 hours to maximize benefit in 60 days mortality (4% vs 12.3%). 91% received CCP with an anti-RBD titer $\geq 1:1350$ . median S/CO ratio =24 using Ortho Vitros.		
	Poland	102 + 102	n.a.	n.a.	n.a.	lower mortality rate (13.7% vs. 34.3%; OR=0.25) related to time of first administration (12.2% at day 5, 21.5% at day 10), no significant differences in ICU stay, ventilator time, and hospitalization time. Earlier administration resulted in a ventilator being needed for a shorter length of time ( $r = 0.41$ )	No failure	(143)
	Brazil	58+116 (kidney transplant recipients)	6 from onset of symptoms	mild and moderate	200 ml	No differences in the need for supplementary oxygen or mechanical ventilation at day 30	only 48% CCP units were high-titer; compared to nonsurvivors, a trend towards a higher proportion of survivors receiving higher-titer CCP	(144)
	Colorado (16 hospitals)	188 + 188	n.a.	n.a.	1 unit if < 90 kg; 2 units if > 90kg	increased length of hospital stay in CCP-treated patients and no change in inpatient mortality compared to controls. In subgroup analysis of CCP-treated patients within 3 or 7 days of admission, there was no difference in length of hospitalization and inpatient mortality.	Covariate matching not achieved for subgroup receiving CCP < 3 days	(145)

683

684

685  
686  
687

## Table 4

Summary of completed but not yet reported or ongoing RCTs of CCP, as registered on ClinicalTrials.gov as of August 26, 2021. BSC: best supportive care; FFP: fresh frozen plasma. Several studies were withdrawn (NCT04377568).

Status	NCT number	Patient subtype	Control arm	Study design	Number planned to enrol	Study start	Locations
Completed	NCT04332835	severe (SOFA <6)	BSC	single masking (outcomes assessor)	92	August 8, 2020	Colombia
	NCT04349410	any	10 different arms	single masking (investigator)	1800	April 11, 2020	USA
	NCT04421404 (CAPRI)	within 3 days from hospitalization or 14 from symptoms	placebo	triple masking (participant, care provider, investigator)	34	June 9, 2020	USA
	NCT04374526	pneumonia, age > 65 and PaO <sub>2</sub> /FiO <sub>2</sub> ≥300 mmHg and comorbidities	BSC	open label	29	May 27, 2020	Italy
	NCT04358783	hospitalized requiring supplemental oxygen	BSC	quadruple masking (participant, care provider, investigator, outcomes assessor)	30	April 27, 2020	Mexico
	NCT04405310	moderate to severe requiring supplemental oxygen	albumin	double (participant, care provider)	80	May 20, 2020	Mexico
	NCT04425915	on ventilator within 3 days from onset of symptoms	BSC	open label	400	June 14, 2020	India
Active, not recruiting	NCT04539275	ventilated and within 3 days from hospitalization	masked saline placebo	triple masking (participant, care provider, investigator)	702	November 16, 2020	USA
	NCT04374487	hospitalized and severe	BSC	open label	100	May 9, 2020	India
	NCT04425837	high-risk	BSC	single masking (outcomes assessor)	236	July 2020	Colombia
	NCT04395170	hospitalized	2 arms (BSC; anti-COVID-19 IVIG)	open label	75	September 2020	Colombia

	NCT04391101	severe	BSC	open label	231	June 2020	Colombia
Recruiting	NCT04516811	moderate to severe	placebo	triple masking (participant, care provider, investigator)	600	September 21, 2020	South Africa
	NCT04388410	hospitalized, severe disease or risk for severe diseases	BSC	quadruple masking (participant, care provider, investigator, outcomes assessor)	410	August 25, 2020	Mexico
	NCT04385043	severe infection	BSC	open label	400	May 1, 2020	Italy
	NCT04380935	acute respiratory distress syndrome	BSC	open label	60	May 18, 2020	Indonesia
	NCT04362176 (PassitOn)	hospitalized adults	placebo	triple masking (participant, care provider, outcomes assessor)	1000	April 24, 2020	USA
	NCT04390503	exposed within 7 days or mild symptoms within 5 days	albumin	double masking (participant, outcome assessor)	150	March 12, 2021	USA
	NCT04376034	severe or life-threatening	BSC	open label	240	March 30, 2021	USA
	NCT04366245	hospitalized ventilated	BSC	open label	72	April 23, 2020	Spain
	NCT04333251	hospitalized within 7 days from symptoms	BSC	open label	115	April 1, 2020	USA
	NCT04345991	mild and within 8 days from symptoms	BSC	open label	120	April 15, 2020	France
	NCT04372979	hospitalized within 10 days from symptoms	FFP	triple masking (participant, care provider, outcomes assessor)	80	September 14, 2020	France
	NCT04345289	adults with pneumonia	placebo	quadruple masking (participant, care provider, investigator, outcomes assessor)	1100	May 1, 2020	Denmark

## 688 References

- 689 1. Casadevall A, Pirofski LA, Joyner MJ. 2021. The Principles of Antibody Therapy for Infectious  
690 Diseases with Relevance for COVID-19. *mBio* 12:e03372-20.
- 691 2. Casadevall A, Pirofski L-a. 2020. The convalescent sera option for containing COVID-19. *The*  
692 *Journal of Clinical Investigation* 130.
- 693 3. Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH. 2010. Hark back:  
694 passive immunotherapy for influenza and other serious infections. *Crit Care Med* 38:e66-73.
- 695 4. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C, Yuan M,  
696 Huang J, Wang Z, Yu J, Gao X, Wang D, Yu X, Li L, Zhang J, Wu X, Li B, Xu Y, Chen W, Peng Y,  
697 Hu Y, Lin L, Liu X, Huang S, Zhou Z, Zhang L, Wang Y, Zhang Z, Deng K, Xia Z, Gong Q, Zhang  
698 W, Zheng X, Liu Y, Yang H, Zhou D, Yu D, Hou J, Shi Z, Chen S, Chen Z, Zhang X, Yang X. 2020.  
699 Effectiveness of convalescent plasma therapy in severe COVID-19 patients. *Proceedings of*  
700 *the National Academy of Sciences* doi:10.1073/pnas.2004168117:202004168.
- 701 5. Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, Kong Y, Ren L, Wei Q, Mei H, Hu C, Tao C, Yang  
702 R, Wang J, Yu Y, Guo Y, Wu X, Xu Z, Zeng L, Xiong N, Chen L, Wang J, Man N, Liu Y, Xu H, Deng  
703 E, Zhang X, Li C, Wang C, Su S, Zhang L, Wang J, Wu Y, Liu Z. 2020. Effect of Convalescent  
704 Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-  
705 threatening COVID-19: A Randomized Clinical Trial. *JAMA* 324:460-470.
- 706 6. Perotti C, Baldanti F, Bruno R, Delfante C, Seminari E, Casari S, Percivalle E, Glingani C,  
707 Musella V, Belliato M, Garuti M, Meloni F, Frigato M, Di Sabatino A, Klersy C, De Donno G,  
708 Franchini M. 2020. Mortality reduction in 46 severe Covid-19 patients treated with  
709 hyperimmune plasma. A proof of concept single arm multicenter interventional trial.  
710 *Haematologica* 105:2834-2840.
- 711 7. Focosi D, Anderson AO, Tang JW, Tuccori M. 2020. Convalescent Plasma Therapy for COVID-  
712 19: State of the Art. *Clin Microbiol Rev* 33:e00072-20.
- 713 8. Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA, Klassen SA, Carter RE, Klompas  
714 AM, Wiggins CC, Shepherd JR, Rea RF, Whelan ER, Clayburn AJ, Spiegel MR, Johnson PW,  
715 Lesser ER, Baker SE, Larson KF, Ripoll JG, Andersen KJ, Hodge DO, Kunze KL, Buras MR, Vogt  
716 MN, Herasevich V, Dennis JJ, Regimbal RJ, Bauer PR, Blair JE, van Buskirk CM, Winters JL,  
717 Stubbs JR, Paneth NS, Verdun NC, Marks P, Casadevall A. 2020. Early safety indicators of  
718 COVID-19 convalescent plasma in 5,000 patients. *J Clin Invest* doi:10.1172/jci140200.
- 719 9. Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES, Wiggins CC,  
720 Bruno KA, Klompas AM, Lesser ER, Kunze KL, Sexton MA, Diaz Soto JC, Baker SE, Shepherd  
721 JRA, van Helmond N, Verdun NC, Marks P, van Buskirk CM, Winters JL, Stubbs JR, Rea RF,  
722 Hodge DO, Herasevich V, Whelan ER, Clayburn AJ, Larson KF, Ripoll JG, Andersen KJ, Buras  
723 MR, Vogt MNP, Dennis JJ, Regimbal RJ, Bauer PR, Blair JE, Paneth NS, Fairweather D, Wright  
724 RS, Casadevall A. 2021. Convalescent Plasma Antibody Levels and the Risk of Death from  
725 Covid-19. *N Engl J Med* 384:1015-1027.
- 726 10. Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P, Latha B, Bundas S,  
727 Kumar V, Dosi R, Khambholja JK, de Souza R, Mesipogu RR, Srivastava S, Dube S, Chaudhary  
728 K, S S, Mattuvar K SA, Rajendran V, Sundararajaperumal A, Balamaniandan P, Maheswari  
729 RSU, Jayanthi R, Ragunathanan S, Bhandari S, Singh A, Pal A, Handa A, Rankawat G,  
730 Kargirwar K, Regi J, Rathod D, Pathrose E, Bhutaka N, Patel MH, Verma RJ, Malukani K, Patel  
731 S, Thakur A, Joshi S, Kulkarni R, Suthar NN, Shah NM, Purohit HM, Shah CK, Patel MN, Shah S,  
732 Shah SH, Memon T, Beriwal VR, et al. 2020. Convalescent plasma in the management of  
733 moderate COVID-19 in India: open-label parallel-arm phase II multicentre randomized  
734 controlled trial (PLACID Trial). *BMJ* 371:m3939.
- 735 11. O'Donnell MR, Grinsztejn B, Cummings MJ, Justman J, Lamb MR, Eckhardt CM, Philip NM,  
736 Cheung YK, Gupta V, João E, Pilotto JH, Diniz MP, Cardoso SW, Abrams D, Rajagopalan K,  
737 Borden S, Wolf A, Sidi LC, Vizzoni A, Veloso VG, Bitan ZC, Scotto DE, Meyer BJ, Jacobson SD,  
738 Kantor A, Mishra N, Chauhan LV, Stone E, Dei Zotti F, La Carpia F, Hudson KE, Ferrera SA,

- 739 Schwartz J, Stotler B, Lin W-H, Wontakal S, Shaz B, Briese T, Hod EA, Spitalnik SL, Eisenberger  
740 A, Lipkin WI. 2021. A randomized, double-blind, controlled trial of convalescent plasma in  
741 adults with severe COVID-19. *J Clin Invest* doi:10.1172/JCI150646:150646.
- 742 12. Simonovich VA, Burgos Pratz LD, Scibona P, Beruto MV, Vallone MG, Vázquez C, Savoy N,  
743 Giunta DH, Pérez LG, Sánchez MdL, Gamarnik AV, Ojeda DS, Santoro DM, Camino PJ, Antelo  
744 S, Rainero K, Vidiella GP, Miyazaki EA, Cornistein W, Trabadelo OA, Ross FM, Spotti M,  
745 Funtowicz G, Scordo WE, Losso MH, Ferniot I, Pardo PE, Rodriguez E, Rucci P, Pasquali J,  
746 Fuentes NA, Esperatti M, Speroni GA, Nannini EC, Matteaccio A, Michelangelo HG, Follmann  
747 D, Lane HC, Belloso WH. 2020. A Randomized Trial of Convalescent Plasma in Covid-19  
748 Severe Pneumonia. *N Engl J Med* 384:619-629.
- 749 13. Pirofski LA, Casadevall A. 2020. Pathogenesis of COVID-19 from the Perspective of the  
750 Damage-Response Framework. *mBio* 11.
- 751 14. Marconato M, Abela IA, Hauser A, Schwarzmüller M, Katzensteiner R, Braun DL, Epp S,  
752 Audige A, Weber J, Rusert P, Schindler E, Pasin C, West E, Boeni J, Kufner V, Huber M, Zaheri  
753 M, Schmutz S, Frey BM, Kouyos RD, Gunthard HF, Manz MG, Trkola A. 2021. Contribution of  
754 endogenous and exogenous antibodies to clearance of SARS-CoV-2 during convalescent  
755 plasma therapy. doi:10.1101/2021.12.09.21267513 %J medRxiv:2021.12.09.21267513.
- 756 15. Van Rompay KKA, Olstad KJ, Sammak RL, Dutra J, Watanabe JK, Usachenko JL, Immareddy R,  
757 Roh JW, Verma A, Lakshmanappa YS, Schmidt BA, Germanio CD, Rizvi N, Stone M, Simmons  
758 G, Dumont LJ, Allen AM, Lockwood S, Pollard RE, de Assis RR, Yee JL, Nham PB, Ardeshir A,  
759 Deere JD, Patterson J, Jain A, Felgner PL, Iyer SS, Hartigan-O'Connor DJ, Busch MP, Reader  
760 JR. 2021. Early post-infection treatment of SARS-CoV-2 infected macaques with human  
761 convalescent plasma with high neutralizing activity reduces lung inflammation.  
762 doi:10.1101/2021.09.01.458520 %J bioRxiv:2021.09.01.458520.
- 763 16. Takamatsu Y, Imai M, Maeda K, Nakajima N, Higashi-Kuwata N, Iwatsuki-Horimoto K, Ito M,  
764 Kiso M, Maemura T, Takeda Y, Omata K, Suzuki T, Kawaoka Y, Mitsuya H. 2021. Highly  
765 Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and  
766 Pneumonia in Syrian Hamsters. *J Virol* doi:10.1128/jvi.01551-21:jvi0155121.
- 767 17. Deere JD, Carroll TD, Dutra J, Fritts L, Sammak RL, Yee JL, Olstad KJ, Reader JR, Kistler A,  
768 Kamm J, Di Germanio C, Shaan Lakshmanappa Y, Elizaldi SR, Roh JW, Simmons G, Watanabe  
769 J, Pollard RE, Usachenko J, Immareddy R, Schmidt BA, O'Connor SL, DeRisi J, Busch MP, Iyer  
770 SS, Van Rompay KKA, Hartigan-O'Connor DJ, Miller CJ. 2021. SARS-CoV-2 Infection of Rhesus  
771 Macaques Treated Early with Human COVID-19 Convalescent Plasma. *Microbiol Spectr*  
772 doi:10.1128/Spectrum.01397-21:e0139721.
- 773 18. Focosi D, Maggi F, Franchini M, Aguzzi A, Lanza M, Mazzoni A, Menichetti F. 2021. Patient-  
774 blood management for COVID19 convalescent plasma therapy: relevance of affinity and  
775 donor-recipient differences in concentration of neutralizing antibodies. *Clin Microbiol Infect*  
776 doi:10.1016/j.cmi.2021.04.003.
- 777 19. Alamgir J, Abid R, Garibaldi BT, Munir N, Setoguchi S, Hong SS, Chen X, Kocis PT, Yajima M,  
778 Alexander GC, Mehta HB, Madhira V, Ergas R, O'Brien TR, Bozzette S. 2021. Lack of  
779 association between convalescent plasma administration and length of hospital stay: a  
780 hospital-day stratified multi-center retrospective cohort study. *medRxiv [Preprint]*  
781 doi:10.1101/2021.05.04.21256627 %J medRxiv:2021.05.04.21256627.
- 782 20. Kocayigit H, Demir G, Karacan A, Süner K, Tomak Y, Yaylacı S, Dheir H, Kalpakci Y, Erdem AF.  
783 2021. Effects on mortality of early vs late administration of convalescent plasma in the  
784 treatment of Covid-19. *Transfus Apher Sci* doi:10.1016/j.transci.2021.103148:103148.
- 785 21. Focosi D, Navarro D, Maggi F, Roilides E, Antonelli G. 2021. COVID-19 infodemics: the role of  
786 mainstream and social media. *Clin Microbiol Infect* doi:10.1016/j.cmi.2021.08.003.
- 787 22. Harrell F, Lindsell C. 2021. Statistical Design and Analysis Plan for Sequential Parallel-Group  
788 RCT for COVID-19.

- 789 23. Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertran MJ, García-Pérez J, Campins M,  
790 Portolés A, González-Pérez M, García Morales MT, Arana-Arri E, Aldea M, Díez-Fuertes F,  
791 Fuentes I, Ascaso A, Lora D, Imaz-Ayo N, Barón-Mira LE, Agustí A, Pérez-Ingidua C, Gómez de  
792 la Cámara A, Arribas JR, Ochando J, Alcamí J, Belda-Iniesta C, Frías J. 2021. Immunogenicity  
793 and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a  
794 multicentre, open-label, randomised, controlled, phase 2 trial. *Lancet* 398:121-130.
- 795 24. WHO. 2020. R & D Blueprint - novel Coronavirus COVID19 Therapeutic Trial Synopsis.  
796 [https://www.who.int/blueprint/priority-diseases/key-action/COVID-](https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf?ua=1)  
797 [19 Treatment Trial Design Master Protocol synopsis Final 18022020.pdf?ua=1.](https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf?ua=1)  
798 Accessed October 1.
- 799 25. Anonymous. 2020. A minimal common outcome measure set for COVID-19 clinical research.  
800 *Lancet Infect Dis* 20:e192-e197.
- 801 26. Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G,  
802 O'Keefe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu  
803 Y, Philley JV, Devine MS, Desruisseaux MS, Santin AD, Anjan S, Mathew R, Patel B, Nigo M,  
804 Upadhyay R, Kupferman T, Dentino AN, Nanchal R, Merlo CA, Hager DN, Chandran K, Lai JR,  
805 Rivera J, Bikash CR, Lasso G, Hilbert TP, Paroder M, Asencio AA, Liu M, Petkova E, Bragat A,  
806 Shaker R, McPherson DD, Sacco RL, Keller MJ, Grudzen CR, Hochman JS, Pirofski LA,  
807 Parameswaran L, et al. 2021. Efficacy and Safety of COVID-19 Convalescent Plasma in  
808 Hospitalized Patients: A Randomized Clinical Trial. *JAMA Intern Med*  
809 doi:10.1001/jamainternmed.2021.6850.
- 810 27. Korley FK, Durkalski-Mauldin V, Yeatts SD, Schulman K, Davenport RD, Dumont LJ, El Kassar  
811 N, Foster LD, Hah JM, Jaiswal S, Kaplan A, Lowell E, McDyer JF, Quinn J, Triulzi DJ, Van  
812 Huysen C, Stevenson VLW, Yadav K, Jones CW, Kea B, Burnett A, Reynolds JC, Greineder CF,  
813 Haas NL, Beiser DG, Silbergleit R, Barsan W, Callaway CW. 2021. Early Convalescent Plasma  
814 for High-Risk Outpatients with Covid-19. *N Engl J Med* doi:10.1056/NEJMoa2103784.
- 815 28. Millat-Martinez P, Gharbharan A, Alemany A, Rokx C, GeurtsvanKessel C, Papageorgiou G,  
816 van Geloven N, Jordans C, Groeneveld G, Swaneveld F, van der Schoot E, Corbacho-Monne  
817 M, Ouchi D, Ferreira FP, Malchair P, Videla S, Garcia VG, Ruiz-Comellas A, Ramirez-Morros A,  
818 Codina JR, Simon RA, Grifols J-R, Blanco J, Blanco I, Ara J, Bassat Q, Clotet B, Baro B, Troxel A,  
819 Zwaginga JJ, Mitja O, Rijnders B. 2021. Convalescent plasma for outpatients with early  
820 COVID-19. doi:10.1101/2021.11.30.21266810 %J medRxiv:2021.11.30.21266810.
- 821 29. Sullivan D, Gebo K, Shoham S, Bloch E, Lau B, Shenoy A, Mosnaim G, Gniadek T, Fukuta Y,  
822 Patel B, Heath S, Levine A, Meisenberg B, Spivak E, Anjan S, Huaman M, Blair J, Currier J,  
823 Paxton J, Gerber J, Petrini J, Broderick P, Rausch W, Cordisco M, J H, Greenblatt B, Cluzet V,  
824 Cruser D, Oei K, Abinante M, Hammitt L, Sutcliffe C, Forthal D, Zand M, Cachay E, Raval J,  
825 Kassaye S, Foster E, Roth M, Marshall C, Yarava A, Lane K, McBee N, Gawad A, Karlen N,  
826 Singh A, Ford D, Jabs D, Appel L, Shade D, et al. 2021. Randomized Controlled Trial of Early  
827 Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma. medRxiv.
- 828 30. Shoham S, Bloch EM, Casadevall A, Hanley D, Lau B, Gebo K, Cachay E, Kassaye SG, Paxton  
829 JH, Gerber J, Levine AC, Currier J, Patel B, Allen ES, Anjan S, Appel L, Baksh S, Blair PW,  
830 Bowen A, Broderick P, Caputo CA, Cluzet V, Cordisco ME, Cruser D, Ehrhardt S, Forthal D,  
831 Fukuta Y, Gawad A, Gniadek T, Hammel J, Huaman MA, Jabs DA, Jedlicka A, Karlen N, Klein S,  
832 Laeyendecker O, Lane K, McBee N, Meisenberg B, Merlo C, Mosnaim G, Park H-S, Pekosz A,  
833 Petrini J, Rausch W, Shade DM, Shapiro J, Singleton JR, Sutcliffe C, Thomas DL, et al. 2021.  
834 Randomized controlled trial transfusing convalescent plasma as post-exposure prophylaxis  
835 against SARS-CoV-2 infection. doi:10.1101/2021.12.13.21267611 %J  
836 medRxiv:2021.12.13.21267611.
- 837 31. Focosi D, Mazzetti P, Pistello M, Maggi F. 2020. Viral infection neutralization tests: a focus on  
838 SARS-CoV-2 with implications for convalescent plasma therapy. *Rev Med Virol* 31:e2170.

- 839 32. Nguyen D, Simmonds P, Steenhuis M, Wouters E, Desmecht D, Garigliany M, Romano M,  
840 Barbezange C, Maes P, Van Holm B, Mendoza J, Oyonarte S, Fomsgaard A, Lassaunière R,  
841 Zusinaite E, Resman Rus K, Avšič-Županc T, Reimerink JH, Brouwer F, Hoogerwerf M,  
842 Reusken CB, Grodeland G, Le Cam S, Gallian P, Amroun A, Brisbarre N, Martinaud C, Leparç  
843 Goffart I, Schrezenmeier H, Feys HB, van der Schoot CE, Harvala H. 2021. SARS-CoV-2  
844 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody  
845 titres for better use of convalescent plasma and comparability of trial data. *Euro Surveill* 26.  
846 33. Devos T, Van Thillo Q, Compernelle V, Najdovski T, Romano M, Dauby N, Jadot L, Leys M,  
847 Maillart E, Loof S, Seyler L, Moonen M, Moutschen M, Van Regenmortel N, Ariën KK,  
848 Barbezange C, Betraïns A, Garigliany M, Engelen MM, Gyselinck I, Maes P, Schauwvlieghe A,  
849 Liesenborghs L, Belmans A, Verhamme P, Meyfroidt G. 2021. Early high antibody-titre  
850 convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. *Eur Respir J*  
851 doi:10.1183/13993003.01724-2021.  
852 34. Estcourt LJ, Turgeon AF, McQuilten ZK, McVerry BJ, Al-Beidh F, Annane D, Arabi YM, Arnold  
853 DM, Beane A, Bégin P, van Bentum-Puijk W, Berry LR, Bhimani Z, Birchall JE, Bonten MJM,  
854 Bradbury CA, Brunkhorst FM, Buxton M, Callum JL, Chassé M, Cheng AC, Cove ME, Daly J,  
855 Derde L, Detry MA, De Jong M, Evans A, Fergusson DA, Fish M, Fitzgerald M, Foley C,  
856 Goossens H, Gordon AC, Gosbell IB, Green C, Haniffa R, Harvala H, Higgins AM, Hills TE, Hoad  
857 VC, Horvat C, Huang DT, Hudson CL, Ichihara N, Laing E, Lamikanra AA, Lamontagne F, Lawler  
858 PR, Linstrum K, Litton E, et al. 2021. Effect of Convalescent Plasma on Organ Support-Free  
859 Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. *JAMA* 326:1690-  
860 1702.  
861 35. Gharbharan A, Jordans CCE, GeurtsvanKessel C, den Hollander JG, Karim F, Mollema FPN,  
862 Stalenhoeft JE, Dofferhoff A, Ludwig I, Koster A, Hassing R-J, Bos JC, van Pottelberge GR,  
863 Vlasveld IN, Ammerlaan HSM, Segarceanu E, Miedema J, van der Eerden M, Papageorgiou G,  
864 te Broekhorst P, Swaneveld FH, Katsikis PD, Mueller Y, Okba NMA, Koopmans MPG,  
865 Haagmans BL, Rokx C, Rijnders B. 2021. Effects of potent neutralizing antibodies from  
866 convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. *Nat Comm*  
867 12:3189.  
868 36. Del Fante C, Franchini M, Baldanti F, Percivalle E, Glingani C, Marano G, Mengoli C,  
869 Mortellaro C, Viarengo G, Perotti C, Liumbruno GM. 2020. A retrospective study assessing  
870 the characteristics of COVID-19 convalescent plasma donors and donations. *Transfusion*  
871 61:830-838.  
872 37. Mehew J, Johnson R, Roberts D, Harvala H. 2020. Convalescent plasma for COVID-19: male  
873 gender, older age and hospitalisation associated with high neutralising antibody levels,  
874 England, 22 April to 12 May 2020. *Euro Surveill* 25:2001754.  
875 38. Mattiuzzo P, Bentley E, Hassal M, Routley S, Richardson S, Bernasconi V, Kristianse P, Harvala  
876 H, Roberts D, Semple M, Turtle L, Openshaw P, Baillie K. 2020. Establishment of the WHO  
877 International Standard and Reference Panel for Anti-SARS-CoV-2 Antibody; WHO Expert  
878 Committee on Biological Standardization: Geneva, Switzerland (2020) WHO/BS/2020.2403.  
879 39. Klingler J, Weiss S, Itri V, Liu X, Oguntuyo KY, Stevens C, Ikegame S, Hung C-T, Enyindah-  
880 Asonye G, Amanat F, Baine I, Arinsburg S, Bandres JC, Kojic EM, Stoeber J, Jurczynszak D,  
881 Bermudez-Gonzalez M, Simon V, Nádas A, Liu S, Lee B, Krammer F, Zolla-Pazner S, Hioe CE.  
882 2020. Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2. *J Infect Dis*  
883 223:957-970.  
884 40. Egloff SAA, Junglen A, Restivo JSA, Wongskhaluang M, Martin C, Doshi P, Schlauch D, Fromell  
885 G, Sears LE, Correll M, Burris HA, LeMaistre CF. 2021. Convalescent plasma associates with  
886 reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19. *J*  
887 *Clin Invest* doi:10.1172/JCI151788.  
888 41. Natarajan H, Crowley AR, Butler SE, Xu S, Weiner JA, Bloch EM, Littlefield K, Wieland-Alter  
889 W, Connor RI, Wright PF, Benner SE, Bonny TS, Laeyendecker O, Sullivan D, Shoham S, Quinn

- 890 TC, Larman HB, Casadevall A, Pekosz A, Redd AD, Tobian AAR, Ackerman ME. 2021. Markers  
891 of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma. *mBio* 12.
- 892 42. Focosi D, Franchini M. 2021. Impact of pathogen-reduction technologies on COVID-19  
893 convalescent plasma potency. *Transfus Clin Biol* 28:132-134.
- 894 43. Bojadzic D, Alcazar O, Buchwald P. 2021. Methylene Blue Inhibits the SARS-CoV-2 Spike-  
895 ACE2 Protein-Protein Interaction—a Mechanism that can Contribute to its Antiviral Activity  
896 Against COVID-19. 11.
- 897 44. Ross V. 1938. Photodynamic Action of Methylene Blue on Antipneumococcal Serum.  
898 *35:351-369*.
- 899 45. Menichetti F, Popoli P, Puopolo M, Spila Alegiani S, Tiseo G, Bartoloni A, De Socio G, Luchi S,  
900 Blanc P, Puoti M, De Donno G, Toschi E, Massari M, Palmisano L, Marano G, Chiamenti M,  
901 Martinelli L, Franchi S, Pallotto C, Suardi L, Luciani Pasqua B, Merli M, Fabiani P, Bertolucci L,  
902 Borchi B, Modica S, Moneta S, Marchetti G, d'Arminio Monforte A, Stoppini L, Ferracchiato  
903 N, Piconi S, Fabbri C, Beccastrini E, Saccardi R, Giacometti A, Esperti S, Pierotti P, Bernini I,  
904 Bianco C, Benedetti S, Lanzi A, Bonfanti P, Massari M, Sani S, Saracino A, Castagna A, Trabace  
905 I, Lanza M, Focosi D, et al. 2021. Effect of High-Titer Convalescent Plasma on Progression to  
906 Severe Respiratory Failure or Death in Hospitalized Patients with COVID-19 Pneumonia: A  
907 Randomized Clinical Trial. Submitted 4:e2136246.
- 908 46. AlQahtani M, Abdulrahman A, Almadani A, Alali SY, Al Zamrooni AM, Hejab AH, Conroy RM,  
909 Wasif P, Atkin SL, Otoom S, Abduljalil M. 2020. Randomized controlled trial of convalescent  
910 plasma therapy against standard therapy in patients with severe COVID-19 disease. *Sci Rep*  
911 *11:9927*.
- 912 47. Avendano-Sola C, Ramos-Martinez A, Munez-Rubio E, Ruiz-Antoran B, Malo de Molina R,  
913 Torres F, Fernandez-Cruz A, Callejas-Diaz A, Calderon J, Payares-Herrera C, Salcedo I, Romera  
914 I, Lora-Tamayo J, Mancheno-Losa M, Paciello ML, Villegas C, Estrada V, Saez-Serrano I,  
915 Porrás-Leal ML, Jarilla-Fernandez MdC, Pano-Pardo JR, Moreno-Chulilla JA, Arrieta-Aldea I,  
916 Bosch A, Belhassen-Garcia M, Lopez-Villar O, Ramos-Garrido A, Blanco L, Madrigal ME,  
917 Contreras E, Muniz-Diaz E, Domingo-Morera JM, Casas-Flecha I, Perez-Olmeda M, Garcia-  
918 Perez J, Alcami J, Bueno JL, Duarte RF. 2021. A multicenter randomized open-label clinical  
919 trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. *J Clin Invest*  
920 doi:10.1172/JCI152740:152740.
- 921 48. Raster J, Zimmermann K, Wesche J, Aurich K, Greinacher A, Selleng K. 2021. Effect of  
922 Methylene Blue Pathogen Inactivation on the Integrity of Immunoglobulin M and G.  
923 *Transfusion Medicine and Hemotherapy* 48:148-153.
- 924 49. Horby PW, Estcourt L, Peto L, Emberson JR, Staplin N, Spata E, Pessoa-Amorim G, Campbell  
925 M, Roddick A, Brunskill NE, George T, Zehnder D, Tiberi S, Aung NN, Uriel A, Widdrington J,  
926 Koshy G, Brown T, Scott S, Baillie JK, Buch MH, Chappell LC, Day JN, Faust SN, Jaki T, Jeffery  
927 K, Juszczak E, Lim WS, Montgomery A, Mumford A, Rowan K, Thwaites G, Mafham M,  
928 Roberts D, Haynes R, Landray MJ. 2021. Convalescent plasma in patients admitted to  
929 hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.  
930 *Lancet* 397:2049-2059.
- 931 50. Bahnan W, Wrighton S, Sundwall M, Bläckberg A, Larsson O, Höglund U, Khakzad H,  
932 Godzwon M, Walle M, Elder E, Happonen L, André O, Kumra Ahnslide J, Hellmark T, Wendel-  
933 Hansen V, Wallin RP, Malmström J, Malmström L, Ohlin M, Rasmussen M, Nordenfelt P.  
934 2021. Opsonization by non-neutralizing antibodies can confer protection to SARS-CoV-2  
935 despite Spike-dependent modulation of phagocytosis. doi:10.1101/2021.10.14.464464 %J  
936 bioRxiv:2021.10.14.464464.
- 937 51. Koerper S, Weiss M, Zickler D, Wiesmann T, Zacharowski K, Corman VM, Gruener B, Ernst L,  
938 Spieth P, Lepper PM, Bentz M, Zinn S, Paul G, Kalbhenn J, Dollinger M, Rosenberger P,  
939 Kirschning T, Thiele T, Appl T, Mayer B, Schmidt M, Drosten C, Wulf H, Kruse JM, Jungwirth B,  
940 Seifried E, Schrezenmeier H. 2021. Results of the CAPSID randomized trial for high-dose



- 941 convalescent plasma in severe COVID-19 patients. *J Clin Invest*  
942 doi:10.1172/JCI152264:2021.05.10.21256192.
- 943 52. Kunze KL, Johnson PW, van Helmond N, Senefeld JW, Petersen MM, Klassen SA, Wiggins CC,  
944 Klompas AM, Bruno KA, Mills JR, Theel ES, Buras MR, Golafshar MA, Sexton MA, Diaz Soto JC,  
945 Baker SE, Shepherd JRA, Verdun NC, Marks P, Paneth NS, Fairweather D, Wright RS, van  
946 Buskirk CM, Winters JL, Stubbs JR, Senese KA, Pletsch MC, Buchholtz ZA, Rea RF, Herasevich  
947 V, Whelan ER, Clayburn AJ, Larson KF, Ripoll JG, Andersen KJ, Lesser ER, Vogt MNP, Dennis JJ,  
948 Regimbal RJ, Bauer PR, Blair JE, Casadevall A, Carter RE, Joyner MJ. 2021. Mortality in  
949 individuals treated with COVID-19 convalescent plasma varies with the geographic  
950 provenance of donors. *Nat Commun* 12:4864.
- 951 53. Rochman ND, Wolf YI, Faure G, Mutz P, Zhang F, Koonin EV. 2021. Ongoing global and  
952 regional adaptive evolution of SARS-CoV-2. *Proc Natl Acad Sci U S A* 118.
- 953 54. Focosi D, Tuccori M, Baj A, Maggi F. 2021. SARS-CoV-2 Variants: A Synopsis of In Vitro  
954 Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal  
955 Antibodies. *Viruses* 13.
- 956 55. Junker D, Dulovic A, Becker M, Wagner TR, Kaiser PD, Traenkle B, Rothbauer U, Kienzle K,  
957 Bunk S, Strümper C, Häberle H, Schmauder K, Malek N, Althaus K, Koeppen M, Bitzer M,  
958 Göpel S, Schneiderhan-Marra N. 2021. Reduced serum neutralization capacity against SARS-  
959 CoV-2 variants in a multiplex ACE2 RBD competition assay  
960 doi:10.1101/2021.08.20.21262328, p 2021.08.20.21262328.
- 961 56. Bennett-Guerrero E, Romeiser JL, Talbot LR, Ahmed T, Mamone LJ, Singh SM, Hearing JC,  
962 Salman H, Holiprosad DD, Freedenberg AT, Carter JA, Browne NJ, Cosgrove ME, Shevik ME,  
963 Generale LM, Andrew MA, Nachman S, Fries BC. 2021. Severe Acute Respiratory Syndrome  
964 Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019  
965 Infected Hospitalized Patients in New York: A Double-Blind Randomized Trial. *Crit Care Med*  
966 doi:10.1097/ccm.0000000000005066.
- 967 57. Bajpai M, Kumar S, Maheshwari A, Chhabra K, kale P, Gupta A, Narayanan A, Gupta E,  
968 Trehanpati N, Bihari C, Agarwal R, Gupta K, Gupta Uk, Bhardwaj A, Kumar G, Islam M, Singh  
969 R, Yadav P, Maiwall R, Sarin SK. 2020. Efficacy of Convalescent Plasma Therapy compared to  
970 Fresh Frozen Plasma in Severely ill COVID-19 Patients: A Pilot Randomized Controlled Trial.  
971 medRxiv [Preprint] doi:10.1101/2020.10.25.20219337 %J medRxiv:2020.10.25.20219337.
- 972 58. Group RC, Horby PW, Mafham M, Peto L, Campbell M, Pessoa-Amorim G, Spata E, Staplin N,  
973 Emberson JR, Prudon B, Hine P, Brown T, Green CA, Sarkar R, Desai P, Yates B, Bewick T,  
974 Tiberi S, Felton T, Baillie JK, Buch MH, Chappell LC, Day JN, Faust SN, Jaki T, Jeffery K,  
975 Juszczak E, Lim WS, Montgomery A, Mumford A, Rowan K, Thwaites G, Weinreich DM,  
976 Haynes R, Landray MJ. 2021. Casirivimab and imdevimab in patients admitted to hospital  
977 with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.  
978 doi:10.1101/2021.06.15.21258542 %J medRxiv:2021.06.15.21258542.
- 979 59. Anonymous. 2020. Dexamethasone in Hospitalized Patients with Covid-19. 384:693-704.
- 980 60. Senefeld JW, Johnson PW, Kunze KL, van Helmond N, Klassen SA, Wiggins CC, Bruno KA,  
981 Golafshar MA, Petersen MM, Buras MR, Klompas AM, Sexton MA, Diaz Soto JC, Baker SE,  
982 Shepherd JRA, Verdun NC, Marks P, van Buskirk CM, Winters JL, Stubbs JR, Rea RF,  
983 Herasevich V, Whelan ER, Clayburn AJ, Larson KF, Ripoll JG, Andersen KJ, Vogt MNP, Dennis  
984 JJ, Regimbal RJ, Bauer PR, Blair JE, Wright K, Greenshields JT, Paneth NS, Fairweather D,  
985 Wright RS, Casadevall A, Carter RE, Joyner MJ. 2021. Program and patient characteristics for  
986 the United States Expanded Access Program to COVID-19 convalescent plasma. medRxiv  
987 [Preprint] doi:10.1101/2021.04.08.21255115 %J medRxiv:2021.04.08.21255115.
- 988 61. Joyner MJ, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES, Wiggins CC, Bruno KA,  
989 Klompas AM, Lesser ER, Kunze KL, Sexton MA, Diaz Soto JC, Baker SE, Shepherd JRA, van  
990 Helmond N, van Buskirk CM, Winters JL, Stubbs JR, Rea RF, Hodge DO, Herasevich V, Whelan  
991 ER, Clayburn AJ, Larson KF, Ripoll JG, Andersen KJ, Buras MR, Vogt MNP, Dennis JJ, Regimbal

- 992 RJ, Bauer PR, Blair JE, Paneth NS, Fairweather D, Wright RS, Carter RE, Casadevall A. 2020.  
993 Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19:  
994 Initial Three-Month Experience. medRxiv [Preprint] doi:10.1101/2020.08.12.20169359 %J  
995 medRxiv:2020.08.12.20169359.
- 996 62. Gonzalez SE, Regairaz L, Salazar M, Ferrando N, Gonzalez V, Carrera Ramos P, Pesci S, Vidal  
997 JM, Kreplak N, Estenssoro E. 2021. Timing of Convalescent plasma administration and 28-day  
998 mortality for COVID-19 pneumonia. doi:10.1101/2021.02.02.21250758 %J  
999 medRxiv:2021.02.02.21250758.
- 1000 63. Yoon Ha, Bartash R, Gendlina I, Rivera J, Nakouzi A, Bortz RH, Wirchnianski AS, Paroder M,  
1001 Fehn K, Serrano-Rahman L, Babb R, Sarwar UN, Haslwanter D, Laudermilch E, Florez C,  
1002 Dieterle ME, Jangra RK, Fels JM, Tong K, Mariano MC, Vergnolle O, Georgiev GI, Herrera NG,  
1003 Malonis RJ, Quiroz JA, Morano NC, Krause GJ, Sweeney JM, Cowman K, Allen S, Annam J,  
1004 Applebaum A, Barboto D, Khokhar A, Lally BJ, Lee A, Lee M, Malaviya A, Sample R, Yang XA,  
1005 Li Y, Ruiz R, Thota R, Barnhill J, Goldstein DY, Uehlinger J, Garforth SJ, Almo SC, Lai JR, Gil MR,  
1006 et al. 2021. Treatment of Severe COVID-19 with Convalescent Plasma in the Bronx, NYC. JCI  
1007 Insight doi:10.1172/jci.insight.142270:142270.
- 1008 64. Liu STH, Lin H-M, Baine I, Wajnberg A, Gumprecht JP, Rahman F, Rodriguez D, Tandon P,  
1009 Bassily-Marcus A, Bander J, Sanky C, Dupper A, Zheng A, Nguyen FT, Amanat F, Stadlbauer D,  
1010 Altman DR, Chen BK, Krammer F, Mendu DR, Firpo-Betancourt A, Levin MA, Bagiella E,  
1011 Casadevall A, Cordon-Cardo C, Jhang JS, Arinsburg SA, Reich DL, Aberg JA, Bouvier NM. 2020.  
1012 Convalescent plasma treatment of severe COVID-19: a propensity score-matched control  
1013 study. *Nature Medicine* 26:1708-1713.
- 1014 65. Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, Lopez BV, Eagar TN, Yi X,  
1015 Zhao P, Rogers J, Shehabeldin A, Joseph D, Leveque C, Olsen RJ, Bernard DW, Gollihar J,  
1016 Musser JM. 2020. Treatment of Coronavirus Disease 2019 Patients with Convalescent  
1017 Plasma Reveals a Signal of Significantly Decreased Mortality. *Am J Pathol* 190:2290-2303.
- 1018 66. Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, Lopez BV, Eagar TN, Yi X,  
1019 Zhao P, Rogers J, Shehabeldin A, Joseph D, Masud F, Leveque C, Olsen RJ, Bernard DW,  
1020 Gollihar J, Musser JM. 2021. Significantly Decreased Mortality in a Large Cohort of  
1021 Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma  
1022 Containing High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)  
1023 Spike Protein IgG. *Am J Pathol* 191:90-107.
- 1024 67. Rogers R, Shehadeh F, Mylona EK, Rich J, Neill M, Touzard-Romo F, Geffert S, Larkin J, Bailey  
1025 JA, Lu S, Sweeney J, Mylonakis E. 2020. Convalescent plasma for patients with severe COVID-  
1026 19: a matched cohort study. *Clin Infect Dis* ciaa1548:Epub ahead of print.
- 1027 68. Briggs N, Gormally MV, Li F, Browning SL, Treggiari MM, Morrison A, Laurent-Rolle M, Deng  
1028 Y, Hendrickson JE, Tormey CA, Desruisseaux MS. 2021. Early but not late convalescent  
1029 plasma is associated with better survival in moderate-to-severe COVID-19. *PLoS One*  
1030 16:e0254453.
- 1031 69. Shenoy AG, Hettlinger AZ, Fernandez SJ, Blumenthal J, Baez V. 2021. Early mortality benefit  
1032 with COVID-19 convalescent plasma: a matched control study. *Br J Haematol*  
1033 doi:10.1111/bjh.17272.
- 1034 70. Arnold Egloff SA, Junglen A, Restivo JSA, Wongsakhaulung M, Martin C, Doshi P, Schlauch D,  
1035 Fromell G, Sears LE, Correll M, Burris HA, LeMaistre CF. 2021. Association of Convalescent  
1036 Plasma Treatment with Reduced Mortality and Improved Clinical Trajectory in Patients  
1037 Hospitalized with COVID-19 in the Community Setting. doi:10.1101/2021.06.02.21258190  
1038 %J medRxiv:2021.06.02.21258190.
- 1039 71. Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, Esteban I, Caballero MT,  
1040 Wood C, Berrueta M, Rondan A, Lescano G, Cruz P, Ritou Y, Fernández Viña V, Álvarez Paggi  
1041 D, Esperante S, Ferreti A, Ofman G, Ciganda Á, Rodríguez R, Lantos J, Valentini R, Itcovici N,  
1042 Hintze A, Oyarvide ML, Etchegaray C, Neira A, Name I, Alfonso J, López Castelo R, Caruso G,

- 1043 Rapelius S, Alvez F, Etchenique F, Dimase F, Alvarez D, Aranda SS, Sánchez Yanotti C, De Luca  
1044 J, Jares Baglivo S, Laudanno S, Nowogrodzki F, Larrea R, Silveyra M, Leberzstein G, Debonis A,  
1045 Molinos J, González M, Perez E, et al. 2021. Early High-Titer Plasma Therapy to Prevent  
1046 Severe Covid-19 in Older Adults. *N Engl J Med* 384:610-618.
- 1047 72. Ray Y, Paul SR, Bandopadhyay P, D'Rozario R, Sarif J, Lahiri A, Bhowmik D, Vasudevan JS,  
1048 Maurya R, Kananan A, Sharma S, Kumar M, Singh P, Roy R, Chaudhury K, Maiti R, Bagchi S,  
1049 Maiti A, Perwez MM, Mondal A, Tewari A, Mandal S, Roy A, Saha M, Biswas D, Maiti C,  
1050 Chakraborty S, Sarkar BS, Haldar A, Saha B, Sengupta S, Pandey R, Chatterjee S, Bhattacharya  
1051 P, Paul S, Ganguly D. 2020. Clinical and immunological benefits of convalescent plasma  
1052 therapy in severe COVID-19: insights from a single center open label randomised control  
1053 trial. medRxiv [Preprint] doi:10.1101/2020.11.25.20237883 %J  
1054 medRxiv:2020.11.25.20237883.
- 1055 73. Epstein J, Burnouf T. 2020. Points to consider in the preparation and transfusion of COVID-19  
1056 convalescent plasma. *Vox Sang* 115:485-487.
- 1057 74. Holm K, Lundgren M, Kjeldsen-Kragh J, Ljungquist O, Bottiger B, Wiken C, Oberg J, Fernstrom  
1058 N, Rosendal E, Overby A, Bystrom J, Forsell M, Landin-Olsson M, Rasmussen M. 2021.  
1059 Convalescent plasma treatment of COVID-19: Results from a prematurely terminated  
1060 randomized controlled open-label study in Southern Sweden. *BMC Research Note* 14:440.
- 1061 75. Klassen SA, Senefeld JW, Johnson PW, Carter RE, Wiggins CC, Shoham S, Grossman BJ,  
1062 Henderson JP, Musser J, Salazar E, Hartman WR, Bouvier NM, Liu STH, Pirofski LA, Baker SE,  
1063 van Helmond N, Wright RS, Fairweather D, Bruno KA, Wang Z, Paneth NS, Casadevall A,  
1064 Joyner MJ. 2021. The Effect of Convalescent Plasma Therapy on Mortality Among Patients  
1065 With COVID-19: Systematic Review and Meta-analysis. *Mayo Clin Proc* 96:1262-1275.
- 1066 76. Janiaud P, Axfors C, Schmitt AM, Gloy V, Ebrahimi F, Hepprich M, Smith ER, Haber NA,  
1067 Khanna N, Moher D, Goodman SN, Ioannidis JPA, Hemkens LG. 2021. Association of  
1068 Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A  
1069 Systematic Review and Meta-analysis. *JAMA* 325:1185-1195.
- 1070 77. Piechotta V, Iannizzi C, Chai KL, Valk SJ, Kimber C, Dorando E, Monsef I, Wood EM, Lamikanra  
1071 AA, Roberts DJ, McQuilten Z, So-Osman C, Estcourt LJ, Skoetz N. 2021. Convalescent plasma  
1072 or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.  
1073 *Cochrane Database Syst Rev* 5:Cd013600.
- 1074 78. Axfors C, Janiaud P, Schmitt AM, Van't Hooft J, Smith ER, Haber NA, Abayomi A, Abduljalil M,  
1075 Abdulrahman A, Acosta-Ampudia Y, Aguilar-Guisado M, Al-Beidh F, Alejandria MM, Alfonso  
1076 RN, Ali M, AlQahtani M, AlZamrooni A, Anaya JM, Ang MAC, Aomar IF, Argumanis LE,  
1077 Averyanov A, Baklaushev VP, Balionis O, Benfield T, Berry S, Birocco N, Bonifacio LB, Bowen  
1078 AC, Bown A, Cabello-Gutierrez C, Camacho B, Camacho-Ortiz A, Campbell-Lee S, Cao DH,  
1079 Cardesa A, Carnate JM, Castillo GJJ, Cavallo R, Chowdhury FR, Chowdhury FUH, Ciccone G,  
1080 Cingolani A, Climacosa FMM, Compennolle V, Cortez CFN, Costa Neto A, D'Antico S, Daly J,  
1081 Danielle F, et al. 2021. Association between convalescent plasma treatment and mortality in  
1082 COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials.  
1083 *BMC Infect Dis* 21:1170.
- 1084 79. Hamilton FW, Lee TC, Arnold DT, Lilford RJ, Hemming K. 2021. Is convalescent plasma futile  
1085 in COVID-19? A Bayesian re-analysis of the RECOVERY randomised controlled trial. *Int J*  
1086 *Infect Dis* S1201-9712:00523-3.
- 1087 80. Cruciani M, Bongiovanni G, Franchini M. 2021. High-titer convalescent plasma therapy for  
1088 coronavirus disease 2019 and mortality. *Transfusion* 61:1988-1990.
- 1089 81. Klassen SA, Senefeld JW, Senese KA, Johnson PW, Wiggins CC, Baker SE, van Helmond N,  
1090 Bruno KA, Pirofski LA, Shoham S, Grossman BJ, Henderson JP, Wright RS, Fairweather D,  
1091 Paneth NS, Carter RE, Casadevall A, Joyner MJ. 2021. Convalescent Plasma Therapy for  
1092 COVID-19: A Graphical Mosaic of the Worldwide Evidence. *Front Med (Lausanne)* 8:684151.

- 1093 82. Casadevall A, Grossman BJ, Henderson JP, Joyner MJ, Paneth NS, Pirofski LA, Shoham S.  
1094 2021. Please Reevaluate the Data on Convalescent Plasma for COVID-19.  
1095 [https://www.medpagetoday.com/opinion/second-opinions/94256?xid=nl\\_mpt\\_DHE\\_2021-08-30&eun=g1783322d0r&utm\\_source=Sailthru&utm\\_medium=email&utm\\_campaign=Daily%20Headlines%20Top%20Cat%20HeC%20%202021-08-30&utm\\_term=NL\\_Daily\\_DHE\\_dual-gmail-definition](https://www.medpagetoday.com/opinion/second-opinions/94256?xid=nl_mpt_DHE_2021-08-30&eun=g1783322d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=Daily%20Headlines%20Top%20Cat%20HeC%20%202021-08-30&utm_term=NL_Daily_DHE_dual-gmail-definition). Accessed August 31, 2021.
- 1096  
1097  
1098  
1099
- 1100 83. Agarwal A, Rochweg B, Siemieniuk RA, Agoritsas T, Lamontagne F, Askie L, Lytvyn L, Leo Y-S, Macdonald H, Zeng L, Amin W, Burhan E, Bausch FJ, Calfee CS, Cecconi M, Chanda D, Du B, Geduld H, Gee P, Harley N, Hashimi M, Hunt B, Kabra SK, Kanda S, Kim Y-J, Kissoon N, Kwizera A, Mahaka I, Manai H, Mino G, Nsutebu E, Preller J, Pshenichnaya N, Qadir N, Sabzwari S, Sarin R, Shankar-Hari M, Sharland M, Shen Y, Ranganathan SS, Souza JP, Stegemann M, De Sutter A, Ugarte S, Venkatapuram S, Dat VQ, Vuyiseka D, Wijewickrama A, Maguire B, Zeraatkar D, et al. 2020. A living WHO guideline on drugs for covid-19. *370:m3379*.
- 1101  
1102  
1103  
1104  
1105  
1106  
1107
- 1108 84. Schrezenmeier H, de Angelis V, Bégué S, Cannata L, Erikstrup C, Escourt L, Feys H, Hartmann C, Lembo M, Mori G, Roberts D, van der Schoot E, Thijssen-Timmer D, Tiberghien P. 2021. COVID-19 convalescent plasma should be further investigated! <https://www.bmj.com/content/370/bmj.m3379/rapid-responses>. Accessed December 21, 2021.
- 1109  
1110  
1111  
1112
- 1113 85. de Candia P, Prattichizzo F, Garavelli S, La Grotta R, De Rosa A, Pontarelli A, Parrella R, Ceriello A, Matarese G. 2021. Effect of time and titer in convalescent plasma therapy for COVID-19. *iScience* doi:10.1016/j.isci.2021.102898:102898.
- 1114  
1115
- 1116 86. Kloypan C, Saesong M, Sangsuemoon J, Chantharit P, Mongkhon P. 2021. Convalescent Plasma for COVID-19: A Meta-analysis of Clinical Trials and Real-World Evidence. *Eur J Clin Invest* doi:10.1111/eci.13663:e13663.
- 1117  
1118
- 1119 87. Franchini M, Focosi D, Corsini F, Cruciani M. 2021. Safety and efficacy of convalescent plasma in COVID-19: an overview of systematic reviews. *Diagnostics* 11:1663.
- 1120
- 1121 88. Bar K, Shaw P, Choi G, Aquí N, Fesnak A, Yang J, Soto-Calderon H, Grajales L, Starr J, Andronov M, Mastellone M, Amonu C, Feret G, DeMarshall M, Buchanan M, Caturla M, Gordon J, Wanicur A, Monroy M, Mampe FL, E, Gouma S, Mullin A, Barilla H, Pronina A, Irwin L, Thomas R, Eichinger R, Demuth F, Prak E, Pascual J, Short W, Elovitz M, Baron J, Meyer N, Degnan K, Frank I, Hensley S, Siegel D, Tebas P. 2021. A Randomized, Controlled Study of Convalescent Plasma for Individuals Hospitalized with COVID-19 Pneumonia. *J Clin Invest* 131:e155114.
- 1122  
1123  
1124  
1125  
1126  
1127
- 1128 89. Anonymous. 2021. Continuous Monitoring of Pooled International Trials of Convalescent Plasma for COVID-19 Hospitalized Patients. <https://med.nyu.edu/departments-institutes/population-health/divisions-sections-centers/biostatistics/research/continuous-monitoring-pooled-international-trials-convalescent-plasma-covid19-hospitalized-patients>. Accessed August 31, 2021.
- 1129  
1130  
1131  
1132
- 1133 90. Focosi D, Franchini M, Pirofski L-a, Burnouf T, Fairweather D, Joyner MJ, Casadevall A. 2021. COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors. *Viruses* 13:1594.
- 1134  
1135
- 1136 91. Franchini M, Cruciani M. 2021. How Safe Is COVID-19 Convalescent Plasma? *Mayo Clin Proc* 96:2279-2281.
- 1137
- 1138 92. Joyner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW, Lesser ER, Wiggins CC, Senefeld JW, Klompas AM, Hodge DO, Shepherd JR, Rea RF, Whelan ER, Clayburn AJ, Spiegel MR, Baker SE, Larson KF, Ripoll JG, Andersen KJ, Buras MR, Vogt MN, Herasevich V, Dennis JJ, Regimbal RJ, Bauer PR, Blair JE, van buskirk CM, Winters JL, Stubbs JR, van Helmond N, Butterfield BP, Sexton M, Diaz Soto J, Paneth NS, Verdun NC, Marks P, Casadevall A, Fairweather D, Carter
- 1139  
1140  
1141  
1142

- 1143 RE, Wright RS. 2020. Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized  
1144 Patients. *Mayo Clinic Proceedings* 95:1888-95.
- 1145 93. Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. 2020. Antibody-dependent enhancement and  
1146 SARS-CoV-2 vaccines and therapies. *Nature Microbiology* 5:1185-1191.
- 1147 94. Focosi D, Novazzi F, Genoni A, Dentali F, Dalla Gasperina D, Baj AM, F. 2021. Emergence of  
1148 SARS-CoV-2 Spike Escape Mutation Q493R After Treatment for COVID-19. *Emerg Infect Dis*  
1149 27.
- 1150 95. Guigon A, Faure E, Lemaire C, Chopin M, Tinez C, Assaf A, Lazrek M, Hober D, Bocket L,  
1151 Engelmann I, Kazali Alidjinou E. 2021. Emergence of Q493R mutation in SARS-CoV-2 spike  
1152 protein during bamlanivimab/etesevimab treatment and resistance to viral clearance. *J*  
1153 *Infect* S0163-4453:00435-7.
- 1154 96. Jensen B, Luebke N, Feldt T, Keitel V, Brandenburger T, Kindgen-Milles D, Lutterbeck M,  
1155 Freise NF, Schoeler D, Haas R, Dilthey A, Adams O, Walker A, Timm J, Luedde T. 2021.  
1156 Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients  
1157 treated with bamlanivimab in Germany. *The Lancet Regional Health – Europe* 8.
- 1158 97. Pommeret F, Colomba J, Bigenwald C, Laparra A, Bockel S, Bayle A, Michot JM, Hueso T,  
1159 Albiges L, Tiberghien P, Marot S, Jary A, Lacombe K, Barlesi F, Griscelli F, Colomba E. 2021.  
1160 Bamlanivimab+ etesevimab therapy induces SARS-CoV-2 immune escape mutations and  
1161 secondary clinical deterioration in COVID-19 patients with B-cell malignancies. *Annals of*  
1162 *Oncology* doi:10.1016/j.annonc.2021.07.015.
- 1163 98. Focosi D, Franchini M. 2021. Potential use of convalescent plasma for SARS-CoV-2  
1164 prophylaxis and treatment in immunocompromised and vulnerable populations. *Expert Rev*  
1165 *Vaccines* doi:10.1080/14760584.2021.1932475:1-8.
- 1166 99. Anonymous. 2021. CoVig-19 Plasma Alliance Announces Topline Results from NIH-  
1167 Sponsored Clinical Trial of Investigational COVID-19 Hyperimmune Globulin Medicine.  
1168 [https://www.takeda.com/newsroom/newsreleases/2021/covig-19-plasma-alliance-](https://www.takeda.com/newsroom/newsreleases/2021/covig-19-plasma-alliance-announces-topline-results-from-nih-sponsored-clinical-trial-of-investigational-covid-19-hyperimmune-globulin-medicine/)  
1169 [announces-topline-results-from-nih-sponsored-clinical-trial-of-investigational-covid-19-](https://www.takeda.com/newsroom/newsreleases/2021/covig-19-plasma-alliance-announces-topline-results-from-nih-sponsored-clinical-trial-of-investigational-covid-19-hyperimmune-globulin-medicine/)  
1170 [hyperimmune-globulin-medicine/](https://www.takeda.com/newsroom/newsreleases/2021/covig-19-plasma-alliance-announces-topline-results-from-nih-sponsored-clinical-trial-of-investigational-covid-19-hyperimmune-globulin-medicine/). Accessed April 2, 2021.
- 1171 100. Anonymous. 2020. ACTIV-3/TICO LY-CoV555 Study Group. A Neutralizing Monoclonal  
1172 Antibody for Hospitalized Patients with Covid-19. *N Engl J Med* 384:905-914.
- 1173 101. Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb RL, Chen P, Hebert C, Perry R, Boscia J,  
1174 Heller B, Morris J, Crystal C, Igbinalolor A, Huhn G, Cardona J, Shawa I, Kumar P, Adams AC,  
1175 Van Naarden J, Custer KL, Durante M, Oakley G, Schade AE, Holzer TR, Ebert PJ, Higgs RE,  
1176 Kallewaard NL, Sabo J, Patel DR, Dabora MC, Klekotka P, Shen L, Skovronsky DM. 2021.  
1177 Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. *N Engl J Med* 385:1382-1392.
- 1178 102. Oladunjoye O, Gallagher M, Wasser T, Oladunjoye A, Paladugu S, Donato A. 2021. Mortality  
1179 due to COVID-19 infection: A comparison of first and second waves. *J Community Hosp*  
1180 *Intern Med Perspect* 11:747-752.
- 1181 103. Casadevall A, Dragotakes Q, Johnson PW, Senefeld JW, Klassen SS, Wright SR, Joyner MJ,  
1182 Paneth N, Carter R. 2021. Convalescent Plasma Use in the United States was inversely  
1183 correlated with COVID-19 Mortality: Did Convalescent Plasma Hesitancy cost lives? *Elife*  
1184 4:e69866.
- 1185 104. Focosi D, Franchini M. 2021. COVID-19 convalescent plasma therapy: hit fast, hit hard! . *Vox*  
1186 *Sang*.
- 1187 105. Focosi D, Franchini M. 2021. COVID-19 neutralizing antibody-based therapies in humoral  
1188 immune deficiencies: A narrative review. *Transfus Apher Sci*  
1189 doi:10.1016/j.transci.2021.103071:103071.
- 1190 106. Senefeld JW, Klassen SA, Ford SK, Senese KA, Wiggins CC, Bostrom BC, Thompson MA, Baker  
1191 SE, Nicholson WT, Johnson PW, Carter RE, Henderson JP, Hartman WR, Pirofski LA, Wright  
1192 RS, Fairweather L, Bruno KA, Paneth NS, Casadevall A, Joyner MJ. 2021. Use of convalescent  
1193 plasma in COVID-19 patients with immunosuppression. *Transfusion* 61:2503-2511.

- 1194 107. Thompson MA, Henderson JP, Shah PK, Rubinstein SM, Joyner MJ, Choueiri TK, Flora DB,  
1195 Griffiths EA, Gulati AP, Hwang C, Koshkin VS, Papadopoulos EB, Robilotti EV, Su CT, Wulff-  
1196 Burchfield EM, Xie Z, Yu PP, Mishra S, Senefeld JW, Shah DP, Warner JL. 2021. Association of  
1197 Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and  
1198 COVID-19. *JAMA Oncol* doi:10.1001/jamaoncol.2021.1799.
- 1199 108. Casadevall A, Henderson J, Joyner M, Pirofski L-a. 2021. SARS-Cov2 variants and  
1200 convalescent plasma: reality, fallacies, and opportunities. *The Journal of Clinical*  
1201 *Investigation* doi:10.1172/JCI148832.
- 1202 109. Bégin P, Callum J, Jamula E, Cook R, Heddle NM, Tinmouth A, Zeller MP, Beaudoin-Bussièrès  
1203 G, Amorim L, Bazin R, Loftsgard KC, Carl R, Chassé M, Cushing MM, Daneman N, Devine DV,  
1204 Dumaresq J, Fergusson DA, Gabe C, Glesby MJ, Li N, Liu Y, McGeer A, Robitaille N, Sachais BS,  
1205 Scales DC, Schwartz L, Shehata N, Turgeon AF, Wood H, Zarychanski R, Finzi A, Marceau D,  
1206 Huang A, Carr H, Lin Y, Lall R, Graham C, Arsenault C, Sales V, Sidhu D, Semret M, Hamm C,  
1207 Arhanchiague E, Solh Z, Srour N, Soliman K, Yee C, Laroche V, Nahirniak S, et al. 2021.  
1208 Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized  
1209 controlled trial. *Nature Medicine* doi:10.1038/s41591-021-01488-2.
- 1210 110. Chalmers TC, Matta RJ, Smith H, Jr., Kunzler AM. 1977. Evidence favoring the use of  
1211 anticoagulants in the hospital phase of acute myocardial infarction. *N Engl J Med* 297:1091-  
1212 6.
- 1213 111. Vickers MA, Sariol A, Leon J, Ehlers A, Locher AV, Dubay KA, Collins L, Voss D, Odle AE, Holida  
1214 M, Merrill AE, Perlman S, Knudson CM. 2021. Exponential increase in neutralizing and spike  
1215 specific antibodies following vaccination of COVID-19 convalescent plasma donors.  
1216 *Transfusion* 61:2099-2106.
- 1217 112. Schmidt F, Weisblum Y, Rutkowska M, Poston D, Da Silva J, Zhang F, Bednarski E, Cho A,  
1218 Schaefer-Babajew DJ, Gaebler C, Caskey M, Nussenzweig MC, Hatzioannou T, Bieniasz PD.  
1219 2021. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. *Nature*  
1220 doi:10.1038/s41586-021-04005-0.
- 1221 113. Germanio CD, Simmons G, Thorbrogger C, Martinelli R, Stone M, Gniadek T, Busch MP. 2021.  
1222 Vaccination of COVID-19 Convalescent Plasma Donors Increases Binding and Neutralizing  
1223 Antibodies Against SARS-CoV-2 Variants. doi:10.1101/2021.10.28.21265622 %J  
1224 medRxiv:2021.10.28.21265622.
- 1225 114. Sheffield WP, Bhakta V, Howell A, Jenkins C, Serrano K, Johnson N, Lin Y-CJ, Colwill K, Rathod  
1226 B, Greenberg B, Gingras A-C, Evans DH, Flaumenhaft E, Beckett A, Drews SJ, Devine DV.  
1227 Retention of hemostatic and immunological properties of frozen plasma and COVID-19  
1228 convalescent apheresis fresh-frozen plasma produced and freeze-dried in Canada. n/a.
- 1229 115. Wilhelm A, Widera M, Grikscheit K, Toptan T, Schenk B, Pallas C, Metzler M, Kohmer N,  
1230 Hoehl S, Helfritz FA, Wolf T, Goetsch U, Ciesek S. 2021. Reduced Neutralization of SARS-CoV-  
1231 2 Omicron Variant by Vaccine Sera and monoclonal antibodies.  
1232 doi:10.1101/2021.12.07.21267432 %J medRxiv:2021.12.07.21267432.
- 1233 116. Cao YR, Wang J, Jian F, Xiao T, Song W, Yisimayi A, Huang W, Li Q, Wang P, An R, Wang J,  
1234 Wang Y, Niu X, Yang S, Liang H, Sun H, Li T, Yu Y, Cui Q, Liu S, Yang X, Du S, Zhang Z, Hao X,  
1235 Shao F, Jin R, Wang X, Xiao J, Wang Y, Xie XS. 2021. B.1.1.529 escapes the majority of SARS-  
1236 CoV-2 neutralizing antibodies of diverse epitopes. doi:10.1101/2021.12.07.470392 %J  
1237 bioRxiv:2021.12.07.470392.
- 1238 117. Focosi D, Maggi F, Franchini M, McConnell S, Casadevall A. 2021. ANALYSIS OF IMMUNE  
1239 ESCAPE VARIANTS FROM ANTIBODY-BASED THERAPEUTICS AGAINST COVID-19.  
1240 doi:10.1101/2021.11.11.21266207 %J medRxiv:2021.11.11.21266207.
- 1241 118. Moscato G, Mazzetti P, Lucenteforte E, Rosellini A, Cara A, Quaranta P, Mainardi V, Villa P,  
1242 Focosi D, Lanza M, Bianco I, Mazzoni A, Falcone M, Menichetti F, Maggi F, Lai M, Freer G,  
1243 Pistello M. 2021. Assessment of automated high-throughput serological assays for prediction  
1244 of high-titer SARS-CoV-2 neutralizing antibody. *Journal of Clinical Virology Plus* 1:100016.

- 1245 119. Jahrsdörfer B, Kroschel J, Ludwig C, Corman VM, Schwarz T, Körper S, Rojewski M, Lotfi R,  
1246 Weinstock C, Drosten C, Seifried E, Stamminger T, Groß HJ, Schrezenmeier H. 2021.  
1247 Independent Side-by-Side Validation and Comparison of 4 Serological Platforms for SARS-  
1248 CoV-2 Antibody Testing. *J Infect Dis* 223:796-801.
- 1249 120. Di Germanio C, Simmons G, Kelly K, Martinelli R, Darst O, Azimpouran M, Stone M, Hazegh K,  
1250 Grebe E, Zhang S, Ma P, Orzechowski M, Gomez JE, Livny J, Hung DT, Vassallo R, Busch MP,  
1251 Dumont LJ. 2021. SARS-CoV-2 Antibody persistence in COVID-19 convalescent plasma  
1252 donors: Dependency on assay format and applicability to serosurveillance. *Transfusion*  
1253 doi:10.1111/trf.16555:2021.03.24.21254260.
- 1254 121. Misset B, Hoste E, Donneau A-F, Grimaldi D, Meyfroidt G, Moutschen M, Compennolle V,  
1255 Gothot A, Desmecht D, Garigliany M, Najdovski T, Laterre P-F. 2020. A multicenter  
1256 randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with  
1257 Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the  
1258 CONFIDENT trial protocol. *BMC Pulmonary Medicine* 20:317.
- 1259 122. Mariën J, Ceulemans A, Michiels J, Heyndrickx L, Kerkhof K, Foque N, Widdowson MA,  
1260 Mortgat L, Duysburgh E, Desombere I, Jansens H, Van Esbroeck M, Ariën KK. 2021.  
1261 Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in  
1262 severe and mild COVID-19 cases using a Luminex bead-based assay. *J Virol Methods*  
1263 288:114025.
- 1264 123. Betrains A, Godinas L, Woei AJF, Rosseels W, Van Herck Y, Lorent N, Dierickx D, Compennolle  
1265 V, Meyfroidt G, Vanderbeke L, Vergote V, Lagrou K, Verhamme P, Wauters J, Vermeersch P,  
1266 Devos T, Maes P, Vanderschueren S. 2021. Convalescent plasma treatment of persistent  
1267 severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with  
1268 lymphoma with impaired humoral immunity and lack of neutralising antibodies. *Br J*  
1269 *Haematol* 192:1100-1105.
- 1270 124. Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, Lamers MM,  
1271 Sikkema RS, de Bruin E, Chandler FD, Yazdanpanah Y, Le Hingrat Q, Descamps D, Houhou-  
1272 Fidouh N, Reusken C, Bosch BJ, Drosten C, Koopmans MPG, Haagmans BL. 2020. Severe  
1273 Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus  
1274 Disease Patients. *Emerg Infect Dis* 26:1478-1488.
- 1275 125. Amanat F, White KM, Miorin L, Strohmeier S, McMahon M, Meade P, Liu W-C, Albrecht RA,  
1276 Simon V, Martinez-Sobrido L, Moran T, García-Sastre A, Krammer F. 2020. An In Vitro  
1277 Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening. 58:e108.
- 1278 126. Walker GJ, Naing Z, Ospina Stella A, Yeang M, Caguicla J, Ramachandran V, Isaacs SR,  
1279 Agapiou D, Bull RA, Stelzer-Braid S, Daly J, Gosbell IB, Hoad VC, Irving DO, Pink JM, Turville S,  
1280 Kelleher AD, Rawlinson WD. 2021. SARS Coronavirus-2 Microneutralisation and Commercial  
1281 Serological Assays Correlated Closely for Some but Not All Enzyme Immunoassays. *Viruses*  
1282 13.
- 1283 127. Abe KT, Li Z, Samson R, Samavarchi-Tehrani P, Valcourt EJ, Wood H, Budyłowski P, Dupuis  
1284 AP, II, Girardin RC, Rathod B, Wang JH, Barrios-Rodiles M, Colwill K, McGeer AJ, Mubareka S,  
1285 Gommerman JL, Durocher Y, Ostrowski M, McDonough KA, Drebot MA, Drews SJ, Rini JM,  
1286 Gingras A-C. 2020. A simple protein-based surrogate neutralization assay for SARS-CoV-2. *JCI*  
1287 *Insight* 5.
- 1288 128. De Santis G, Oliveira L, Garibaldi P, Almado C, Croda J, Arcanjo G, Oliveira E, Tonacio A,  
1289 Langhi D, Bordin J, Gilio R, Palma L, Santos E, Haddad S, Prado B, Pontelli M, Gomes R,  
1290 Miranda C, Martins M, Covas DA, E, Fonseca B, Calado R. 2021. High-dose convalescent  
1291 plasma for the treatment of severe COVID-19: a multicenter randomized clinical trial. *Int J*  
1292 *Infect Dis*.
- 1293 129. Oguntuyo KY, Stevens CS, Hung C-T, Ikegame S, Acklin JA, Kowdle SS, Carmichael JC, Chiu H-  
1294 p, Azarm KD, Haas GD, Amanat F, Klingler J, Baine I, Arinsburg S, Bandres JC, Siddiquey MN,  
1295 Schilke RM, Woolard MD, Zhang H, Duty AJ, Kraus TA, Moran TM, Tortorella D, Lim JK,

- 1296 Gamarnik AV, Hioe CE, Zolla-Pazner S, Ivanov SS, Kamil JP, Krammer F, Lee B. 2020.  
1297 Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus  
1298 neutralization assay allows for cross-cohort comparisons of COVID-19 sera. *mBio* 12.
- 1299 130. Anonymous. Wu, Fan and Wang, Aojie and Liu, Mei and Wang, Qimin and Chen, Jun and Xia,  
1300 Shuai and Ling, Yun and Zhang, Yuling and Xun, Jingna and Lu, Lu and Jiang, Shibo and Lu,  
1301 Hongzhou and Wen, Yumei and Huang, Jinghe, Neutralizing Antibody Responses to SARS-  
1302 CoV-2 in a COVID-19 Recovered Patient Cohort and Their Implications (3/28/2020). Available  
1303 at SSRN: <https://ssrn.com/abstract=3566211> or <http://dx.doi.org/10.2139/ssrn.3566211>.
- 1304 131. Beltrán-Pavez C, Riquelme-Barrios S, Oyarzún-Arrau A, Gaete-Argel A, González-Stegmaier R,  
1305 Cereceda-Solis K, Aguirre A, Travisany D, Palma-Vejares R, Barriga GP, Gaggero A, Martínez-  
1306 Valdebenito C, Corre NL, Ferrés M, Balcells ME, Fernandez J, Ramírez E, Villarroel F, Valiente-  
1307 Echeverría F, Soto-Rifo R. 2021. Insights into neutralizing antibody responses in individuals  
1308 exposed to SARS-CoV-2 in Chile. *7:eabe6855*.
- 1309 132. Dieterle ME, Haslwanter D, Bortz RH, 3rd, Wirchnianski AS, Lasso G, Vergnolle O, Abbasi SA,  
1310 Fels JM, Laudermilch E, Florez C, Mengotto A, Kimmel D, Malonis RJ, Georgiev G, Quiroz J,  
1311 Barnhill J, Pirofski LA, Daily JP, Dye JM, Lai JR, Herbert AS, Chandran K, Jangra RK. 2020. A  
1312 Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated  
1313 Cell Entry and Its Inhibition. *Cell Host Microbe* 28:486-496.e6.
- 1314 133. Rasheed AM, Fatak DF, Hashim HA, Maulood MF, Kabah KK, Almusawi YA, Abdulmir AS.  
1315 2020. The therapeutic potential of convalescent plasma therapy on treating critically-ill  
1316 COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. *Infez Med*  
1317 28:357-366.
- 1318 134. Balcells ME, Rojas L, Le Corre N, Martínez-Valdebenito C, Ceballos ME, Ferrés M, Chang M,  
1319 Vizcaya C, Mondaca S, Huete Á, Castro R, Sarmiento M, Villarroel L, Pizarro A, Ross P,  
1320 Santander J, Lara B, Ferrada M, Vargas-Salas S, Beltrán-Pavez C, Soto-Rifo R, Valiente-  
1321 Echeverría F, Caglevic C, Mahave M, Selman C, Gazitúa R, Briones JL, Villarroel-Espindola F,  
1322 Balmaceda C, Espinoza MA, Pereira J, Nervi B. 2020. Early Anti-SARS-CoV-2 Convalescent  
1323 Plasma in Patients Admitted for COVID-19: A Randomized Phase II Clinical Trial. *PLoS*  
1324 *Medicine* doi:10.1371/journal.pmed.1003415.
- 1325 135. Anonymous. National COVID19 Convalescent Plasma Project. Commentary from the COVID-  
1326 19 Convalescent Plasma Project (CCPP19) Leadership Group on "Early Convalescent Plasma  
1327 for High-Risk Outpatients with Covid-19". Accessed online at  
1328 [https://ccpp19.org/news/review%20of%20NEJM%20US%20outpatient%20CP%20trial%208-](https://ccpp19.org/news/review%20of%20NEJM%20US%20outpatient%20CP%20trial%208-23.docx)  
1329 [23.docx](https://ccpp19.org/news/review%20of%20NEJM%20US%20outpatient%20CP%20trial%208-23.docx) on August 25, 2021.
- 1330 136. Anonymous. March 2, 2021. NIH halts trial of COVID-19 convalescent plasma in emergency  
1331 department patients with mild symptoms. [https://www.nih.gov/news-events/news-](https://www.nih.gov/news-events/news-releases/nih-halts-trial-covid-19-convalescent-plasma-emergency-department-patients-mild-symptoms)  
1332 [releases/nih-halts-trial-covid-19-convalescent-plasma-emergency-department-patients-](https://www.nih.gov/news-events/news-releases/nih-halts-trial-covid-19-convalescent-plasma-emergency-department-patients-mild-symptoms)  
1333 [mild-symptoms](https://www.nih.gov/news-events/news-releases/nih-halts-trial-covid-19-convalescent-plasma-emergency-department-patients-mild-symptoms). Accessed
- 1334 137. Beltran Gonzalez JL, Gonzalez Gamez M, Mendoza Enciso EA, Esparza Maldonado RJ,  
1335 Hernandez Palacios D, Duenas Campos S, Ovalle Robles I, Macias Guzman MJ, Garcia Diaz AL,  
1336 Gutierrez Pena CM, Reza Escalera AL, Tiscareno Gutierrez MT, Galvan Guerra E, Dorantes  
1337 Morales MdR, Martinez Medina L, Monroy Colin VA, Arreola Guerra JM. 2021. Efficacy and  
1338 safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19  
1339 patients. A controlled clinical trial. *medRxiv [Preprint]* doi:10.1101/2021.03.28.21254507 %J  
1340 *medRxiv*:2021.03.28.21254507.
- 1341 138. Sekine L, Arns B, Fabro BR, Cicolatt MM, Machado RRG, Durigon EL, Parolo E, Pellegrini JAS,  
1342 Viana MV, Schwarz P, Lisboa TC, Dora JMS, Balsan AM, Schirmer FD, Franz JPM, da-Silveira  
1343 LM, Breunig RC, Petersen V, Sosnoski M, Mesquita NF, Volpato FCZ, Sganzerla D, Falavigna  
1344 M, Rosa RG, Zavascki AP. 2021. Convalescent plasma for COVID-19 in hospitalised patients:  
1345 an open-label, randomised clinical trial. *Eur Respir J* doi:10.1183/13993003.01471-2021.



- 1346 139. Devos T, Geukens T, Schauwvlieghe A, Ariën KK, Barbezange C, Cleeren M, Compennolle V,  
1347 Dauby N, Desmecht D, Grimaldi D, Lambrecht BN, Luyten A, Maes P, Moutschen M, Romano  
1348 M, Seyler L, Nevessignsky MT, Vandenberghe K, van Griensven J, Verbeke G, Vlieghe E,  
1349 Yombi JC, Liesenborghs L, Verhamme P, Meyfroidt G. 2020. A randomized, multicentre,  
1350 open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the  
1351 addition of convalescent plasma to the standard of care in patients hospitalized with COVID-  
1352 19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. *Trials* 21:981.
- 1353 140. Jiang W, Li W, Xiong L, Wu Q, Wu J, He B, Shen J, Pang R, Luo T, Guo Y, Yang Y, Han Y, Dai W,  
1354 Zhu P, Xia X. 2020. Clinical efficacy of convalescent plasma therapy on treating COVID-19  
1355 patients: Evidence from matched study and a meta-analysis. *Clin Transl Med* 10:e259.
- 1356 141. Pappa V, Bouchla A, Terpos E, Thomopoulos TP, Rosati M, Stellas D, Antoniadou A, Mentis A,  
1357 Papageorgiou SG, Politou M, Kotanidou A, Kalomenidis I, Poulakou G, Jahaj E, Korompoki E,  
1358 Grigoropoulou S, Hu X, Bear J, Karaliota S, Burns R, Pagoni M, Trontzas I, Grouzi E,  
1359 Labropoulou S, Stamoulis K, Bamias A, Tsiodras S, Felber BK, Pavlakis GN, Dimopoulos MA.  
1360 2021. A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe  
1361 COVID-19- A Propensity Score-Matched Control Analysis. *Microorganisms* 9:806.
- 1362 142. Salazar E, Kuchipudi SV, Christensen PA, Eagar TN, Yi X, Zhao P, Jin Z, Long SW, Olsen RJ,  
1363 Chen J, Castillo B, Leveque C, Towers DM, Lavinder J, Gollihar JD, Cardona J, Ippolito GC,  
1364 Nissly RH, Bird IM, Greenawalt D, Rossi RM, Gontu A, Srinivasan S, Poojary IB, Cattadori IM,  
1365 Hudson PJ, Joselyn N, Prugar L, Huie K, Herbert A, Bernard DW, Dye J, Kapur V, Musser JM.  
1366 2020. Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding  
1367 domain IgG correlate with virus neutralization. *J Clin Invest* 130:6728-6738.
- 1368 143. Tworek A, Jaroń K, Uszyńska-Kałuża B, Rydzewski A, Gil R, Deptała A, Franek E, Wójtowicz R,  
1369 Życińska K, Walecka I, Cicha M, Wierzba W, Zaczyński A, Król ZJ, Rydzewska G. 2021.  
1370 Convalescent plasma treatment is associated with lower mortality and better outcomes in  
1371 high risk COVID-19 patients - propensity score matched case-control study. *Int J Infect Dis*  
1372 105:209-215.
- 1373 144. Cristelli MP, Junior DML, Viana LA, de Andrade LGM, Martins SBS, Dreige YC, Bordim JO,  
1374 Tedesco-Silva H, Medina-Pestana J. 2021. Efficacy of Convalescent Plasma to Treat Mild to  
1375 Moderate COVID-19 in Kidney Transplant Patients: A Propensity Score Matching Analysis.  
1376 *Transplantation* doi:10.1097/tp.0000000000003962.
- 1377 145. Chauhan L, Pattee J, Ford J, Thomas C, Lesteberg K, Richards E, Loi M, Dumont LJ, Annen K,  
1378 Berg M, Zirbes M, Miller A, Jenkins TC, Bennett TD, Monkowski D, Boxer RS, Beckham JD.  
1379 2021. A Multi-center, Prospective, Observational-cohort controlled study of Clinical  
1380 Outcomes following COVID-19 Convalescent plasma therapy in hospitalized COVID-19  
1381 patients. *Clin Infect Dis* doi:10.1093/cid/ciab834:ciab834.

1382

1383 Acknowledgements: this manuscript is written in memory of Dr.Giuseppe De Donno, Director of the  
1384 Pneumology Division at the Mantua Hospital, a pioneer in the field of CCP.

1385

1386

1387 Author biographies :

1388 Daniele Focosi



1389

1390 Dr. Focosi is a hematologist employed since 2009 as resident transfusion physician at the Pisa  
1391 University Hospital. He has formerly been transplant immunologist and immunogeneticist, quality  
1392 assurance manager and production manager at the largest blood bank in Italy. He has received  
1393 awards from the European Federation of Immunogenetics, the European Society of Organ  
1394 Transplantation, and the Italian Society of Hematology. He has a Ph.D. degree in Clinical and  
1395 Fundamental Virology, and a master degree in Clinical trials. He has authored 169 articles on topics  
1396 ranging from emerging viral infections to new markers of immune competence (including more  
1397 than 50 and a SpringerNature book on SARS-CoV-2 evolution), for a h-index of 30.

1398 Massimo Franchini



1399

1400 Dr. Franchini specialized in Hematology (1995) at the University of Verona (Italy). He is currently  
1401 Director of the Department of Hematology and Transfusion Medicine of the Hospital of Mantua (Italy).  
1402 He is associate Editor of Seminars in Thrombosis and Hemostasis, Member of the Committee of the  
1403 Italian Association of Hemophilia Centers (AICE) for the revision of the Italian Guidelines on the  
1404 management of Hemophilia. He is a member of the Regional Hematology Network (REL, Lombardy  
1405 Region) - subcommittee of Hemostasis, and served as consultant of the Italian Ministry of Health –  
1406 National Blood Center (2016-2020). His field of scientific research is predominantly dedicated to  
1407 hemostasis and thrombosis. His is currently studying the COVID-19 convalescent plasma, from  
1408 biological validation to its clinical use. He has authored more than 650 publications for a h-index of 83.

1409

1410 Liise-anne Pirofski



1411

1412 Dr. Liise-anne Pirofski is a physician-scientist. Her research programs focus on immunity to  
1413 encapsulated pathogens and antibody mediated immunity to infectious diseases. She is chief of the  
1414 Division of Infectious Diseases and the Jacques and Selma Mitrani Chair in Biomedical Research at  
1415 Albert Einstein College of Medicine and Montefiore Medical Center. She is a member of the American  
1416 Association of Physicians and a fellow of the American Academy of Microbiology, American College

1417 of Physicians, Infectious Diseases Society of America, and the American Association for the  
1418 Advancement of Science. She is deeply devoted to biomedical education and mentoring for which she  
1419 has received numerous accolades, including the American Society for Microbiology William A Hinton  
1420 Award, and the Albert Einstein College of Medicine Faculty Mentoring Award, Harry Eagle Award for  
1421 Outstanding Basic Science Teaching, and the Lifetime Achievement Award from the Albert Einstein  
1422 College of Medicine Alumni Association.

1423

1424 Thierry Burnouf




1425

1426 Dr. Burnouf is a protein biochemist who has authored more than 280 publications in the field of  
1427 therapeutic blood products for a h-index of 53. He has received the 2019 Award from the International  
1428 Plasma Fractionation Association. His current research interest focuses on Platelet growth factors for  
1429 regenerative medicine and cell therapy, Plasma fractionation, Viral inactivation technologies, and  
1430 Blood biotechnology. He is the Secretary of the Working Party on Global Blood Safety, and the  
1431 Treasurer of the Working Party on Cellular Therapies of the International Society of Blood  
1432 Transfusion.

1433

1434 Nigel Paneth



1435

1436 Dr. Paneth is a pediatrician and perinatal and child health epidemiologist with a particular interest in  
1437 the causes and prevention of childhood neurodevelopmental handicap, especially cerebral palsy  
1438 (CP). He was among the promoters of the US National COVID19 Convalescent Plasma Project  
1439 (CCPP10). He is Emeritus University Distinguished Professor of Epidemiology and Biostatistics and  
1440 Pediatrics has authored more than 320 publications for a h-index of 86.

1441

1442 Michael J. Joyner



1443

1444 Dr. Joyner has authored more than 535 publications for a h-index of 93. His laboratory is  
1445 interested in how humans respond to various forms of physical and mental stress during  
1446 activities such as exercise, hypoxia, standing up and blood loss. Dr. Joyner is leading a  
1447 national program sponsored by the U.S. Government to coordinate the collection and  
1448 distribution of COVID-19 convalescent plasma for the treatment of individuals with severe or  
1449 life-threatening disease.

1450

1451 Arturo Casadevall



1452

1453 He is the chair of the Molecular Microbiology & Immunology, Bloomberg distinguished professor  
1454 Alfred & Jill Sommer professor and chair professor. He has authored more than 900 PubMed-indexed  
1455 articles for a h-index of 133. His research focuses on host defense mechanisms, how fungi cause  
1456 disease, and in the development of antibody-based therapies for infectious diseases.

1457

1458